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91.  INTRODUCTION 
     Coronary artery disease (CAD) is defined as a disease spectrum of varied etiology,
with a common factor being an imbalance between myocardial function and oxygen
supply. This imbalance results from a reduction in coronary blood flow which is mainly
due to atherosclerotic obstruction of coronary arteries. Abnormal concentrations of serum
and lipoprotein cholesterol and serum triglycerides, smoking, obesity, diabetes, and
hypertension are strongly associated with the risk for CAD (Grundy et al 2000). Even
though CAD is the leading cause of death in women, women are often excluded from
epidemiologic or interventional  studies of CAD, or they comprise a minority of study
subjects (Rich-Edwards et al 1995).  
       Among all the other risk factors, high serum cholesterol level is the most prominent
etiologic factor for CAD. Atherosclerotic lesions are interspersed with lipid-laden foam
cells, which are mainly filled with cholesteryl esters (Stary et al 1994). Moreover, high
serum cholesterol levels independently increase the morbidity and mortality of CAD
(Stamler et al 1986, Jousilahti et al 1999), and lowering serum cholesterol levels reduces
coronary morbidity and mortality as well as all-cause mortality (LaRosa et al 1999).
Serum cholesterol concentrations are strongly regulated by receptor-mediated catabolism
of low density lipoprotein (LDL) (Brown et al 1981, Brown and Goldstein 1986), but
also by cholesterol metabolism. Association between cholesterol absorption efficiency
and serum cholesterol level has been demonstrated (Miettinen and Kesäniemi 1989).
Low cholesterol synthesis has been observed in CAD patients with hypercholesterolemia,
but not in normocholesterolemic patients (Miettinen 1971a). Furthermore, low bile acid
synthesis was associated with morbidity and mortality of CAD in patients with familial
hypercholesterolemia (Simonen and Miettinen 1987, Miettinen and Gylling 1988).
Eventually, these studies have raised the question whether cholesterol metabolism also
plays a role in the development of CAD in normocholesterolemic populations. 
        A simple way to assess baseline status and changes in cholesterol metabolism is to
measure squalene and noncholesterol sterols in fasting serum. The squalene molecule is
a triterpene which contains six isoprene units. Squalene is a nonsterol intermediate in the
biosynthetic pathway to cholesterol and is present in various human tissues, such as skin,
adipose and arterial tissues  (Liu et al 1976), and atherosclerotic plaques (Brooks et al
1966). Squalene in human tissues originates mainly from de novo synthesis and partly
from diet, especially from olive oil-rich diet. Serum squalene and demethylated
precursors of cholesterol desmosterol and lathosterol are  associated with cholesterol
synthesis rate (Miettinen 1969, Miettinen et al 1990), even though the association of
squalene with the synthesis rate of cholesterol is controversial (Miettinen 1970). Serum
squalene levels are most likely affected by acute changes in cholesterol metabolism, as
in diurnal variation in cholesterol synthesis (Miettinen 1982a) and after LDL apheresis
(Gylling et al 1998). Endogenous and dietary squalene metabolism has undergone only
limited study in human subjects, and its relation to CAD is virtually unknown. 
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     Dietary squalene in serum, which is mainly carried by intestinally derived
lipoproteins, can be used as a marker for postprandial lipoproteins (Gylling and Miettinen
1994). As early as the 1940s, Moreton observed that after a high fat-meal, plasma
lipoproteins appeared similar to those from hypercholesterolemic patients and proposed
that atherogenesis may be a postprandial phenomenon (Moreton 1947). This hypothesis
was again emphasized (Zilversmit 1979) and has further been investigated by
experimental and case-control studies, in which only men were included or the majority
of the study population were men. In these studies, postprandial lipoproteins are clearly
elevated in men with CAD (Simons et al 1987, Groot et al 1991, Karpe et al 1993a), but
not in women with angina (Ginsberg et al 1995). After a high fat meal, only intermediate
density lipoproteins (IDL) are elevated in women with CAD (Meyer et al 1996).
Accordingly, whether postprandial lipoproteins are atherogenic also in women has not
been convincingly settled.
      Statins, inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase,
are commonly used to reduce serum cholesterol levels, and their hypolipidemic effect is
associated with decreased major coronary events (LaRosa et al 1999). Because statins
inhibit cholesterol synthesis, serum cholesterol precursors are subsequently reduced, but
serum squalene levels are inconsistently altered (Miettinen et al 1992a). Plant sterols
(e.g., campesterol, sitosterol) in the human circulation are solely of dietary origin and
induce cholesterol malabsorption, and thus lower serum cholesterol level. Sitostanol, a
5 -saturated derivative of sitosterol, dissolved in dietary margarine is particularly
effective in reducing cholesterol absorption and serum and LDL cholesterol levels
(Vanhanen et al 1994, Miettinen et al 1995). Because cholesterol malabsorption induced
by sitostanol ester margarine consequently increases cholesterol synthesis, it thus should
have an effect on serum squalene and other cholesterol precursors.  
      This study is therefore focused on squalene, cholesterol metabolism, and postprandial
lipoproteins, and their association with CAD and conventional coronary risk factors in
postmenopausal women. In addition, the effects of sitostanol ester margarine alone and
in combination with statin were related to serum squalene and lipid levels and cholesterol
metabolism in CAD women.
11
2.  REVIEW OF THE LITERATURE
2.1.  Cholesterol metabolism
       Cholesterol is a major component of mammalian cell membranes, particularly of
plasma membranes, and regulates membrane fluidity and permeability. It  is essential for
tissue growth, steroid hormone production in the adrenal glands, ovaries, and testes, for
bile acid synthesis in the liver, and vitamin D production in the skin. The intestinal tract
regulates metabolism of exogenous lipids, while the liver is the major organ for synthesis
and secretion of endogenous lipids and bile acids (Brown et al 1981). 
       Cholesterol has no appreciable aqueous solubility; thus, the transport of cholesterol
in the circulatory system is facilitated by lipoproteins. Lipoproteins are spherical particles
and comprise a hydrophobic core of esterified cholesterol and triglycerides and a
surrounding hydrophilic shell of apolipoproteins (apo’s), phospholipids, and unesterified
cholesterol. According to the density in ultracentrifugation, plasma lipoproteins can be
divided into chylomicrons (<0.95 g/ml), very low density lipoprotein (VLDL: 0.95-1.006
g/ml), IDL (1.006-1.019 g/ml), LDL (1.019-1.063 g/ml), and high density lipoprotein
(HDL: 1.063-1.210 g/ml). Chylomicrons and VLDL are called triglyceride-rich
lipoproteins (TGRL). In normolipidemic humans, about 70% of plasma cholesterol is
carried by LDL. Apolipoproteins, apo As, apo Bs, apo Cs, and apo E  are not only
structural proteins for lipoprotein particles, but are also cofactors for enzymes, ligands
for cell surface receptors, and necessary proteins for lipoprotein production.
       In humans, cholesterol is acquired either by de novo synthesis or by absorption from
the diet. In a particular tissue, cholesterol is either synthesized de novo or is derived from
circulatory lipoproteins. The human body’s cholesterol pool is regulated by the following
factors: 
                                                                                                                                           
1. Dietary intake of cholesterol
2. Intestinal absorption of cholesterol and formation of postprandial lipoproteins
3. Reverse cholesterol transport from peripheral tissues 
4. Hepatic uptake of lipoproteins by receptors
5. Endogenous, mainly hepatic cholesterol synthesis
6. Hepatic secretion of  lipoproteins
7. Bile acid synthesis
8. Uptake of cholesterol by peripheral tissues
9. Biliary excretion and fecal elimination of cholesterol and bile acids. 
                                                                                                                                           
       Under normal conditions, endogenous synthesis of cholesterol contributes two-thirds
of the total cholesterol input into whole-body pools (Dietschy 1984, Miettinen et al
1992b). Cholesterol feeding increases the amount of cholesterol in the body (Wang et al
1957, Grundy and Denke 1990). However, accumulation of cholesterol in tissues by
increased dietary cholesterol intake is prevented through reduced fractional absorption or
12
synthesis of cholesterol or by enhanced cholesterol excretion (Quintao et al 1971,
McNamara et al 1987, Kern  1991, Gylling and Miettinen 1992).  
 
2.1.1.  Cholesterol synthesis 
        Although the liver is the major organ for cholesterol synthesis, most of the human
organs such as the intestine, skin and muscle are capable of synthesizing cholesterol
(Dietschy and Weiss 1971). Cholesterol is synthesized from acetyl-CoA via many
biochemical steps in the cytoplasm, endoplasmic reticulum, or peroxisomes (Biardi and
Krisans 1996). In the liver, acetyl -CoA is derived largely from fatty acids. Theoretically,
the features of cholesterol synthesis can be divided into pre-squalene synthesis (Fig.1)
and post-squalene synthesis (Fig.2). The latter includes cyclization of squalene to
lanosterol, and the metabolic reactions leading from lanosterol to cholesterol. These
pathways share many enzymes, and deficiency in these enzymes disrupts cholesterol
biosynthesis. 
              Acetyl-CoA
                         Condensation of two molecules of acetyl-CoA by acetyl-CoA acetyltransferase
           Acetoacetyl-CoA
                        Condensation with acetyl-CoA by 3-hydroxy-3-methylglutaryl-CoA synthase
  3-hydroxy-3-methylglutaryl-CoA
                        3-hydroxy-3-methylglutaryl-CoA reductase,  NADPH
              Mevalonate
                        Phosphorylation by  mevalonate kinase
       5-phosphomevalonate
                        Phosphorylation by  phosphomevalonate kinase
      5-diphosphomevalonate
                        Decarboxylation and dehydration by diphosphomevalonate decarboxylase
      Isopentenyl diphosphate
                        Isomerisation of   -double bond by isopentenyl diphosphate isomerase3
     Dimethylallyl diphosphate
                        Condensation with isopentenyl diphosphate by prenyltransferase
         Geranyl diphosphate 
                         Condensation with isopentenyl diphosphate by prenyltransferase
      Farnesyl diphosphate (FPP)
                        Tail-to-tail condensation of 2 molecules of FPP by squalene synthase
                Squalene
Fig.1. Pre-squalene cholesterol synthesis
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                     Squalene
                            v A
                  2,3-oxidosqualene
                            V B
 4,4',14"-trimethyl-5"-cholesta-8,24-dien-3$-ol         >  4,4',14"-trimethyl-5"-cholesta-8-en-3$-ol
                       (Lanosterol)                                          D                     (Dihydrolanosterol)
                            V C                                                              v C
    4,4'-dimethyl-5"-cholesta-8,24-dien-3$-ol                  > 4,4'-dimethyl-5"-cholesta-8-en-3$-ol         
         E          v                                                        D               E        V                         
               4"-methyl-5"-cholesta-8,24-dien-3$-ol            >             4"-methyl-5"-cholesta-8-en-3$-ol
                                E                               D                          () -methostenol)8
            V             V                         F                                              V              V E                F  
   5"-cholesta-8,24-dien-3$-ol                                            >    5"-cholesta-8-en-3$-ol              
           (Zymosterol)                                                 D         (Zymostenol/Cholestenol)        
                F                                  v                                            F                             V  
                   4"-methyl-5"-cholesta-7,24-dien-3$-ol       >              4"-methyl-5"-cholesta-7-en-3$-ol
                                                           E                          D                                (Methostenol)
            V                                      V                                                 V                                 V E
           5"-cholesta-7,24-dien-3$-ol                                   >          5"-cholesta-7-en-3$-ol                     
                                 G                                         D                         (Lathosterol)             
                             V                                                                                          v G
           5"-cholesta-5,7,24-trien-3$-ol                               >         5"-cholesta-5,7-dien-3$-ol
                                 H                                         D                    (7-dehydrocholesterol)                 
                              V                                                                                         V H
                5"-cholesta-5,24-dien-3$-ol                               >           5-cholesta-5-en-3-ol             
                      (Desmosterol)                                           D                       (Cholesterol)
      
                        Fig. 2. Post-squalene cholesterol synthesis
A: Oxidation by squalene epoxidase
B : Cyclization by oxidosqualene-lanosterol cyclase
C: Demethylation at C-14 by 14-demethylase and  saturation of  -double bond by  14
     sterol- -reductase14
D: Saturation of  -double bond by  sterol- -reductase24 24
E: Demethylation at C-4 by sterol-4-demethylase
F: Isomerisation of  -double bond by sterol- -isomerase    8 8
G: Introduction of  -double bond by sterol- -desaturase      5 5
H: Saturation of  -double bond by 3 -hydroxy-steroid- -reductase   7 7
   The first and rate-limiting step in cholesterol biosynthesis is the synthesis of
mevalonate from HMG CoA, a process catalyzed by HMG CoA reductase. Squalene is
formed from mevalonate (Fig.1) and further cyclized to lanosterol, the first sterol nucleus
in the cholesterol biosynthesis (Fig.2). The formation of cholesterol from lanosterol
involves three distinct processes: (1) Removal of extra three methyl groups (2) Migration
of the double bond from the 8 to the 5 position in sterol nucleus (3) Reduction of the  -24
double bond. It is commonly believed that 14-methyl group is removed initially, since
14
isomerization of the  -double bond to   does not occur when the 14-methyl group is8 7
present (Gaylor et al 1966). Whether the saturation of  -double bond occurs first, or24
this reduction is the final step, thus far has not been demonstrated in vivo. 
       For measurement of cholesterol synthesis in humans, direct and indirect techniques
exist (Miettinen 1970). These methods are sterol balance (Grundy et al 1969), assay of
HMG CoA reductase activity (Björkhem et al 1987), and tracer incorporation approaches
(e.g., incorporation of various [ C]-substrates, deuterium, and tritium, and mass14
isotopomer distribution analysis) (Dietschy 1984, Buono et al 2000).  The sterol balance
technique provides a direct assessment of endogenous biosynthesis rate, which is
regarded as the difference between fecal excretion of neutral and acidic steroids and total
cholesterol intake. Once internal sterol pools have reached equilibrium, i.e., the steady
state, sterol balance provides an accurate method to assay cholesterol synthesis.
Alternatively, measuring plasma concentrations of cholesterol precursors such as
mevalonate, squalene, methyl sterols, desmosterol, and lathosterol indicates relative
changes in cholesterol synthesis rates (Miettinen 1970, Miettinen 1982a, Parker et al
1984). Cholesterol synthesis rate is regulated by cholesterol feeding as well as by other
dietary factors, intestinal cholesterol absorption, enterohepatic circulation of bile acids
and thyroid hormones (Table 1). In subjects with obesity and in those with diabetes,
cholesterol synthesis is enhanced (Miettinen 1971b, Gylling and Miettinen 1997).   
2.1.2.  Squalene, cholesterol absorption, and postprandial lipoproteins
2.1.2.1.  Squalene
    In 1916, Tsujimoto discovered that liver oil from Squaloid sharks contains a high
proportion of an unsaturated triterpenoid hydrocarbon C H  (Fig.3), which he thus30 50
called squalene. It was reported in 1926 that squalene feeding increased the cholesterol
content in rat liver, and squalene was first proposed as a precursor of cholesterol
(Channon 1926, Helibron et al 1926). Many studies have shown that squalene is
synthesized from acetate and is metabolized to cholesterol (Langdon and Bloch 1953,
Tchen and Bloch 1957, Srikantaiah et al 1976).       
                     
                 Fig.3  A. Squalene                          B. Cholesterol
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Table 1.  Cholesterol synthesis in humans under different conditions
                                                                                                                                                      
       Variable                         Cholesterol synthesis                      Reference 
                                              Effect    Method                                                                            
Dietary intake
   Polyunsaturated fatty acids        SB                                   Conner et al 1969, Nestel et al 1973,
          Grundy 1975
                                         SB, serum lathosterol     Glatz and Katan 1993
   Saturated fatty acids            SB                                Conner et al 1969
           SB, serum lathosterol     Glatz and Katan 1993                
   Squalene                                     SB, serum desmosterol   Strandberg et al 1990
   Cholesterol             SB                                   Lin and Conner 1980, Duane 1993
                                                          [ C]acetate incorpora-14
                                                          tion into leukocytes       McNamara et al 1987
                                                      SB                                    Gylling and Miettinen 1992
   Fibers (pectin, plantago             SB, serum cholesterol      Miettinen and Tarpila 1977, 
         ovata, guar gum)                      precursors                      Miettinen and Tarpila 1989,             
                                                                                  Kesäniemi et al 1990
Cholesterol malabsorption
    Plant sterols and stanols            SB, serum cholesterol     Grundy et al 1969, Vanhanen et al  
               precursors                     1994
    Neomycin                                  SB                                   Kesäniemi and Grundy 1984,
              Gylling and Miettinen 1995
    Jejuno-ileal bypass and            SB, serum cholesterol     Miettinen 1985, Färkkilä et al 1988
       ileal resection                             precursors                    
Interrupted enterohepatic 
 circulation of bile acids           
     Cholestyramine                        SB                                    Grundy et al 1971, Nazir et al 1972
      Jejuno-ileal bypass and           SB, serum cholesterol      Grundy et al 1971, Miettinen 1985, 
           ileal resection                       precursors                         Färkkilä et al 1988
Obesity              SB                                  Miettinen 1971b
Weight reduction              SB               Leijd 1981
Diabetes              SB                                  Gylling and Miettinen 1997
Thyroid hormones                           SB                                  Abrams and Grundy 1981
                                                                                                                                                     
=increase;  =decrease;  =nonsignificant decrease; SB=sterol balance.                 
        The immediate precursor of squalene is farnesyl diphosphate which undergoes tail-
to-tail condensation in the presence of squalene synthetase under anaerobic conditions
(Goodman and Popjak 1960, Bloch 1965, Radisky and Poulter 2000). Squalene further
undergoes cyclization to lanosterol by the action of enzymes (squalene epoxidase)
attached to microsomal particles, depending on oxygen and reduced di- or
triphosphopyridine nucleotides (Tchen and Bloch 1957, Bloch 1965). This oxidative
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process requires the involvement of sterol carrier protein 1 (Scallen et al 1971,
Srikantaiah et al 1976).
    Skin and adipose tissues contain high levels of squalene, whereas liver, large intestine,
and muscle have lower levels (Liu et al 1976, Tilvis and Miettinen 1980). Squalene is
bound to sterol-carrier proteins in hepatocytes (Scallen et al 1971). In fasting plasma,
lipoprotein distribution of squalene varies considerably from subject to subject
(Miettinen 1982a), but in normolipidemic subjects, on average, about 50% (Saudek et al
1978) or even more than 50% (Miettinen 1982a, Gylling and Miettinen 1994) of squalene
is transported in both LDL and HDL, and the rest by VLDL. However, in type III
hyperlipidemic subjects, more than 50% of fasting squalene is transported by VLDL
(Gylling and Miettinen 1994). Furthermore, newly synthesized squalene is found
exclusively in d<1.019 g/ml lipoproteins (Goodman 1964). In familial
hypercholesterolemic patients, approximately 75% of serum squalene is carried by LDL
but after chronic stimulation of cholesterol synthesis by jejuno-ileal bypass, a
considerable amount of squalene (40-60%) is accumulated in VLDL (Miettinen 1985,
Koivisto and Miettinen 1988). During the 24-hour period, squalene levels in VLDL peak
after midnight (at 4 am), reflecting the diurnal variation of cholesterol biosynthesis
(Miettinen 1982a).
    Olive oil is rich in squalene, and cod liver oil and corn oil also contain significant
amounts of squalene (Liu et al 1976). Dietary intake of squalene is approximately 24
mg/day, but it may reach up to 1 g/day in any population consuming olive oil-rich diets.
Squalene feeding increases squalene concentrations in the liver and plasma (Tilvis and
Miettinen 1983a, Liu et al 1976, Strandberg et al 1990, Miettinen and Vanhanen 1994).
Human bile contains a high amount of squalene and thus contributes significantly to the
squalene pool in the intestine.
  
2.1.2.2.  Intestinal absorption of cholesterol, squalene, and other lipids
     The intestinal cholesterol pool consists of a mixture of free and esterified cholesterol,
which originates from the diet, bile, intestinal secretion, and from desquamation of
mucosal cells. In a normal situation, contribution of the two latter variables is minor. The
daily dietary cholesterol ranges from 300 to 500 mg, and the daily flux of biliary
cholesterol into the intestine is approximately 12 to 28 mg/kg (Northfield  and Hofmann
1975). In the diet, a variable proportion of cholesterol is in esterified form, but in the bile,
cholesterol is in unesterified form.The essential features of intestinal cholesterol
absorption include hydrolysis of cholesteryl esters and triglycerides, emulsification,
solubilization of lipids, sterol uptake by the enterocytes, and subsequent transfer of
cholesterol from the mucosal cell into the thoracic lymph duct.
     Dietary long-chain triglycerides and cholesteryl esters are hydrolyzed by pancreatic
triglyceride lipase and cholesterol esterase, respectively, yielding free fatty acids,
monoglycerides, and free cholesterol (Wilson and Rudel 1994). In the presence of
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sufficient concentrations of bile acids, phospholipids, and other amphipathic substances
such as monoglycerides and fatty acids, free cholesterol is solubilized in mixed micelles
in the intestinal lumen. Mixed micelles facilitate lipid movement through the unstirred
water layer, which separates the intraluminal bulk water phase from the brush border
membrane of enterocytes (Westergaard and Dietschy 1976). It is widely believed that
cholesterol movement across the brush border membrane is a passive diffusion according
to the concentration gradient. Recent  reports have indicated that scavenger receptor class
B type I (Hauser et al 1998) and pancreatic cholesterol esterase (Lopez-Candales et al
1993, Howles et al 1996) can mediate the mucosal cholesterol uptake.  Although
unesterified cholesterol is efficiently absorbed, cholesteryl esters are either not absorbed
(Vahouny and Treadwell 1958, Vahouny and Treadwell 1964) or absorbed to some
extent. Carboxyl ester lipase (i.e., pancreatic cholesterol esterase) facilitates absorption
of dietary cholesteryl esters, but not that of unesterified cholesterol (Howles et al 1996).
      In normal humans, approximately 25 to 75% of intraluminal cholesterol is absorbed,
meaning that a marked  interindividual variation does exist (Miettinen et al 1990, Ostlund
et al 1999). The amount of cholesterol absorbed increases dose-dependently with
increasing amount of dietary cholesterol, but cholesterol absorption efficiency decreases
with increasing mass of cholesterol (Quintao et al 1971, Ostlund et al 1999). Cholesterol
absorption also decreases after reduced absorptive area by gut resection or jejuno-ileal
bypass (Färkkilä et al 1988). Deficiency of bile salts, pancreatic enzymes, or acyl-CoA
cholesterol acyltransferase (ACAT) or displacement of cholesterol from the micelles, for
instance by plant sterols or plant stanols can reduce cholesterol absorption (Siperstein et
al 1952, Borja et al 1964, Gallo et al 1984, Armstrong and Carey 1987, Wilson and Rudel
1994, Gylling and Miettinen 1996b). A recent study has suggested that up-regulation of
adenosine triphosphate-binding cassette transporter 1 (ABC1) expression and activation
of retinoid X receptors inhibit cholesterol absorption (Repa et al 2000). 
     Intestinal absorption of squalene in man has been poorly explored. An experimental
rat study revealed that the absorption percentages of dietary squalene, H-labeled 3
squalene, and C-labeled cholesterol were 33%, 42%, and 48%, respectively, during a14
squalene intake of 8 mg, and an increase in unlabeled squalene in the test meal (8 to 48
mg) increased total mass of absorbed squalene, but reduced significantly the absorption
efficiencies of unlabeled and labeled squalene to 21% and 27%, without any influence on
cholesterol absorption efficiency (Tilvis and Miettinen 1983b). In man, short-term
squalene feeding (900 mg/day for 7 days) increased mean fecal squalene output (from 2
to 359 mg/day), and 60% of intestinal squalene has been absorbed without any changes
in cholesterol absorption efficiency by squalene feeding (Strandberg et al 1990).
However, a long-term squalene-feeding study revealed that 85% of ingested dietary
squalene was absorbed (Miettinen and Vanhanen 1994). The capacity of the intestine to
absorb squalene was thus similar to or even higher than its capacity for absorbing
cholesterol.
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2.1.2.3.  Chylomicron formation and mucosal squalene 
     In the smooth endoplasmic reticulum of the intestinal mucosa, monoglycerides and
fatty acids are reesterified to triglycerides via the 2-monoglyceride (by the addition of
two molecules of fatty acids to 2-monoglyceride) or 3-glycero phosphate (by the addition
of 3 molecules of fatty acids to glycerol-3-phosphate) pathways. Free cholesterol is
reesterified by the mediation of cholesterol esterase, ACAT1, and ACAT2 (Borja et al
1964, Gallo et al 1984, Cases et al 1998). Reesterified triglycerides, cholesteryl esters,
and phospholipids, and also apo’s are incorporated into lipoproteins, which are released
into the lamina propria and move via the lymph into the systemic circulation. 
         During fat absorption, chylomicrons are the principal lipoproteins derived from the
enterocytes, but lipoproteins with densities of VLDL and IDL are also synthesized in the
intestine (Ockner et al 1969a, Tytgat et al 1971, Green and Glickman 1981, Karpe et al
1995). The latter lipoproteins are present in intestinal lymph also during the fasting state
(Ockner et al 1969b, Jones and Ockner 1971, Tytgat et al 1971). During increased lipid
flux across the intestinal mucosa, lipoprotein particle size increases to accommodate the
increased lipid mass of the enterocytes, and chylomicrons become the predominant
carrier of these lipids. Alimentary lipoprotein formation and secretion in the intestine are
facilitated by microsomal triglyceride transfer protein (Wetterau et al 1992) and apo B-48
(Green and Glickman 1981, Hamilton et al 1998, Hussain 2000). The intestinal mucosa
also synthesizes substantial amounts of apo A-I and  apo A-IV (Glickman et al 1991). A
newly synthesized chylomicron particle is composed of a large core of triglycerides (85-
92%) and cholesteryl esters (0.8-1.4%), surrounded by a surface layer of phospholipids
(6-12%), free cholesterol (0.8-1.6%), and apo’s (1-2%) such as apo B-48, A-I, and A-IV
(Green and Glickman 1981, Hussain 2000) (Fig. 4). Chylomicrons are heterogeneous in
size, and their diameter ranges from 80 to 800 nm. Newly assembled chylomicrons move
to the Golgi lumen from the endoplasmic reticulum in the enterocytes (Hamilton et al
1998), from which they are released into the intercellular space by reverse pinocytosis,
and are transported to plasma via the thoracic lymph duct. 
    Only a few studies have described the metabolic fate of dietary squalene in the
mucosa. In rats, after a single oral dose of combined  H-labeled squalene and C-labeled3 14
cholesterol, the radioactivity of squalene appeared in the thoracic duct within 2 hours and
peaked at about 12 hours, whereas that of cholesterol peaked at about 24 hours (Tilvis
and Miettinen 1983b). Methyl sterols and cholesterol of chyle were also labeled at 4
hours, suggesting that, in the intestinal mucosa, absorbed squalene is partially
metabolized to sterols. In man, a short-term squalene feeding increased markedly VLDL
squalene concentration relative to that of cholesterol; thus, the squalene to cholesterol
ratio increased more markedly in VLDL than in the other lipoprotein fractions
(Strandberg et al 1990). Furthermore, following a squalene-supplemented fat meal
squalene levels were markedly elevated in chylomicrons (Gylling and Miettinen 1994).
These studies suggest that dietary squalene, similar to cholesterol, is incorporated into
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chylomicrons and is transported into the circulation via the thoracic lymph duct.
2.1.2.4.  Chylomicron remnant formation
      In contact with the capillary endothelium which lines the vascular bed of muscle and
adipose tissues, chylomicron triglycerides are hydrolyzed at the glycerol 1 and 3 positions
to monoglycerides and fatty acids, a process mediated by lipoprotein lipase (Nilsson-Ehle
1980). In fact, most of the triglycerides of chylomicrons are removed by extrahepatic
tissues (Bergman et al 1971), and chylomicron-triglycerides are hydrolyzed rapidly in the
circulation (Nestel 1964). The residual  triglycerides and surface lipids of chylomicrons
such as phospolipids and apo A-I and IV can be transferred to HDL, and conversely,
cholesteryl esters and apo E, C-I, C-II, and C-III of HDL can be transferred to
chylomicrons (Tall 1990). Cholesteryl ester transfer protein plays a key role in the
transport of cholesteryl esters from HDL to chylomicrons. These processes convert
chylomicrons to triglyceride-depleted and cholesterol-enriched chylomicron remnant
particles (Fig.4). The released fatty acids are oxidized in muscle in order to produce
energy or reesterified and stored in the adipose tissues. The monoglycerides are further
hydrolyzed or degraded in the liver, and resynthesized triglycerides are secreted within
VLDL particles. 
     
2.1.2.5.  Hepatic uptake of chylomicron remnants
       Chylomicron remnants are normally cleared rapidly from the circulation (Noel et al
1975, Cooper 1997). While bound to the surface of hepatocytes in the space of Disse,
remnants acquire apo E, secreted by the hepatocytes, and the phospholipids of these
remnants are further hydrolyzed by hepatic lipase. These processes facilitate endocytosis
of the remnants. The remnant uptake is mediated by the LDL receptor, the LDL receptor-
related protein (LRP), and heparan sulfate proteoglycans (HSPG), but also the
involvement of other receptors, such as the asialoglycoprotein receptor, the lipolysis-
stimulated receptor, a TGRL receptor and a lactoferrin-inhibited receptor, has been
reported (Cooper 1997, Mahley  and Ji 1999) (Fig.4). The LDL receptor and LRP
mediate direct uptake of chylomicron remnants via the recognition of apo E. LRP can use
hepatic lipase or lipoprotein lipase as a ligand for the uptake. HSPG alone can also
mediate direct uptake, or transfer remnants to LRP for uptake.   
2.1.2.6.  Quantification of postprandial lipoproteinemia 
    Postprandial lipoproteinemia is defined as a rise and a subsequent return to basal levels
of lipoproteins after a meal. This is reflected as a temporary rise of triglycerides and
cholesterol in these lipoproteins (postprandial lipemia). A simple way of assessing
postprandial lipoproteinemia is measuring plasma triglyceride concentration in
chylomicrons, and in chylomicron remnants (a fraction of which possesses VLDL-
density) after a high fat-meal. Because liver also produces triglyceride-rich particles of
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Fig. 4. Lipoprotein metabolism. 
CETP= cholesteryl ester transfer protein; HL=hepatic lipase; HSPG=heparan sulfate
proteoglycans; LDL-R=LDL receptor; LRP=LDL receptor-related protein;
LPL=lipoprotein lipase.
  
VLDL density, measuring serum triglycerides does not, however, reflect only the
magnitude of postprandial lipoproteinemia. Dietary vitamin A is absorbed as retinol and
esterified in the enterocytes and secreted in chylomicron particles (Goodman et al 1966).
In contrast to triglycerides, retinyl esters are not hydrolyzed during remnant formation,
but only after their uptake by the hepatocytes, are hydrolyzed. From the liver, retinol is
secreted into plasma with retinol-binding protein or is reesterified and stored in the
hepatocytes. Thus, vitamin A added to the fat meal labels the postprandial lipoproteins.
Since the 1970s, vitamin A-fat-loading tests have frequently been used to measure
postprandial lipemia (Hazzard and Bierman 1976, Weintraub et al 1987a). Because a
considerable amount of retinyl palmitate was found in lipoproteins (LDL) other than in
chylomicrons and chylomicron remnants during the later stages of the postprandial phase,
apo B-48 was suggested to be a more specific indicator of intestinally originated
lipoproteins (Krasinski et al 1990a). Unlike other apolipoproteins, apo B-48 remains with
the intestinal lipoprotein particle until its hepatic uptake. Thus, intestinally derived
lipoproteins can be distinguished from those of  hepatic origin by an assay of apo B-48.
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The quantification of apo B-48 is laborious, and thus it is relevant to search for other
postprandial markers. An elevation of squalene levels in the chylomicrons and
chylomicron remnants following a squalene-vitamin A mixed-fat meal suggests that
squalene absorption is similar to that of cholesterol, and serum squalene levels can serve
as markers of intestinal lipoproteins (Gylling and Miettinen 1994).  
2.1.2.7.  Factors influencing postprandial lipoproteinemia
   Many dietary and environmental factors may influence the magnitude of postprandial
lipoproteinemia. Large amounts of fat increase the peak concentration of triglycerides
and cholesteryl esters in intestinally derived lipoproteins (Dubois et al 1998). In contrast
to a diet enriched in saturated fat, a diet enriched in polyunsaturated fatty acids (PUFA),
oat bran, wheat fiber, or wheat germ reduces postprandial lipemia (Weintraub et al 1988,
Cara et al 1992). Old men versus young men (Krasinski et al 1990b, Relas et al: in press),
males versus females (Johnson et al 1992) and obese versus lean subjects (Mekki et al
1999) show pronounced postprandial responses after consuming a fat meal. Physical
exercise is  associated with a reduction in postprandial lipemia (Malkova et al 1999), but
smoking increases postprandial lipoprotein levels (Mero et al 1997). 
     Genes encoding apolipoproteins and enzymes are also involved in remnant clearance.
Subjects with the apo E 2 phenotype show poor clearance of intestinally derived
lipoproteins (Weintraub et al 1987a). Deficiencies in hepatic lipase (Hegele et al 1993),
lipoprotein lipase (Miesenböck et al 1993), and lecithin-cholesterol acyltransferase
(Gylling and Miettinen 1993) enhance the accumulation of remnants.  Furthermore,
increased postprandial lipemia has been reported in apo A-I  carriers versus controlsMilano
(Calabresi et al 1993), in a patient heterozygous for apo A-I  mutation (Leu 159Arg)FIN
versus her controls (Gylling et al 1996), in subjects with apo B X-/X- versus those with
X+ genotypes (Lopez-Miranda et al 1997), and in subjects with apo A-IV-347 Threonine
(controls) versus those with A-IV-347 Serine genotypes (Ostos et al 1998).
2.1.2.8.  Hepatic squalene and cholesterol metabolism
   The intermediary role of squalene in endogenous cholesterol biosynthesis has been well
elucidated. The rapid appearance of [ C]squalene in plasma has been observed after14
intravenous administration of [ C]mevalonate (Goodman 1964,  Liu et al 1975, Saudek14
et al 1978). After 2 days from the administration, virtually all absorbed H-labeled3
squalene was recovered as  H-sterols (mainly cholesterol ) in serum, liver, skin, muscle,3
and adipose tissues (Tilvis and Miettinen 1983b). Squalene feeding markedly raised
serum concentrations of methyl sterols and desmosterol, but lathosterol levels were
inconsistently elevated (Strandberg et al 1990, Miettinen and Vanhanen 1994). Sterol
balance (i.e., cholesterol synthesis) was also increased by squalene feeding (Strandberg
et al 1990), but this increase in cholesterol synthesis was limited to rapeseed oil intake
combined with squalene feeding (Miettinen and Vanhanen 1994). These studies suggest
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that from the circulation, dietary squalene in chylomicrons and chylomicron remnants is
rapidly taken up by the liver, where it is metabolized to sterols.
  Elevation of cholesterol synthesis by cholestyramine raised serum squalene
concentrations (Miettinen 1969, Liu et al 1976). Fasting reduced squalene production as
well as cholesterol synthesis in human adipose tissues in vitro (Tilvis and Miettinen
1979). Furthermore, hypocaloric diets reduced squalene concentrations in fasting serum
(Liu et al 1976). Ileal resection with bile acid and fat malabsorption led to  significant
increases in cholesterol synthesis and serum squalene and cholesterol precursors
(Färkkilä et al 1988). Thus, serum squalene concentrations may reflect the magnitude of
cholesterol synthesis. However, in some studies, in contrast to the demethylated sterols
desmosterol and lathosterols, serum squalene concentrations were inconsistently
associated with cholesterol synthesis rate (Miettinen 1970, Miettinen 1985). Ileal
resection with bile acid malabsorption alone raised levels of all serum cholesterol
precursors, but not that of squalene (Färkkilä et al 1988).         
         In addition to the contribution to cholesterol biosynthesis, a portion of the hepatic
squalene pool is secreted via bile. In fact, the squalene levels are much higher in bile than
in plasma, and in subjects on squalene-free diets, squalene appears also in feces (Liu et
al 1976). In rats, approximately 31% and 34% of absorbed H-labeled squalene were3
excreted as fecal neutral steroids and bile acids, respectively (Tilvis and Miettinen
1983b). In humans, squalene feeding elevated fecal excretion of neutral steroids and bile
acids by 31% and 20%, respectively (Strandberg et al 1990). From human skin,
elimination of squalene does occur, but this is of minor impact in the regulation of
plasma squalene concentrations, since most of the squalene in the skin is synthesized de
novo (Nikkari et al 1974).
      The amount of dietary squalene is inconsistently associated with fasting serum
cholesterol concentrations. Small squalene doses (500 mg/day), in contrast to high doses
(1 g/day), have minor effects on post-squalene cholesterol synthesis and serum
cholesterol levels (Miettinen and Vanhanen 1994). In normolipidemic subjects, short-
term squalene feeding (900 mg in capsules/day) altered serum cholesterol concentrations
and LDL apo B-100 metabolism inconsistently (Miettinen 1986, Strandberg et al 1990),
but in hypercholesterolemic subjects, long-term feeding of 1 g/day of squalene mixed
with rapeseed oil raised total, LDL, VLDL, and IDL cholesterol concentrations as well
as the apo-100 of LDL and VLDL (Miettinen and Vanhanen 1994). In the latter study,
the production rate of apo B-100 was increased, and the catabolic rate of LDL apo B-100
was decreased in those subjects who showed a marked increase in LDL cholesterol
levels, suggesting that the newly synthesized cholesterol derived from dietary squalene
does influence lipoprotein metabolism, and consequently increases serum cholesterol
levels. On the other hand, substituting 100 g/day of olive oil (500 mg of squalene) for the
dietary fat reduced serum cholesterol levels (Miettinen 1986). This reduction was
probably due to the high monounsaturated fatty acid (MUFA) content of the olive oil,
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since MUFA-rich diets do lower serum cholesterol level (Kris-Etherton et al 1999). In
fact, serum cholesterol levels are low in the Mediterranean area, where dietary olive oil
intake is very high (Verschuren et al 1995).
2.1.3.  Serum noncholesterol sterols
2.1.3.1.  Demethylated cholesterol precursors     
    The conversion of lanosterol to cholesterol in the later stages of biosynthetic pathway
may occur by two routes. By one, reduction of the  -double bond is the final step, thus24
generally called the unsaturated side-chain pathway, and the immediate precursor of
cholesterol is desmosterol (Fig.2). By the second pathway, reduction of the   bond24
occurs at the initial stage, and saturation of the  -double bond occurs last, so that this is7
generally called the saturated side-chain pathway.The immediate precursor of cholesterol 
in this pathway is 7-dehydrocholesterol, which ordinarily is barely detectable in normal
serum. Lathosterol is the immediate precursor of  7-dehydrocholesterol. Lathosterol and
desmosterol are the major demethylated precursor sterols present in the fasting serum,
and their serum levels are associated with hepatic HMGCoA reductase activity
(Björkhem et al 1987). Accordingly, the serum concentrations of desmosterol and
lathosterol reflect cholesterol synthesis rate in a normal population (Miettinen  et al
1990).  
2.1.3.2.  Cholestanol and plant sterols
     Cholestanol is a 5 -saturated derivative of cholesterol. Serum cholestanol originates
mainly from endogenous synthesis. The daily cholestanol intake is less than 2 mg in
Finnish population, and less than 5% of intestinal cholestanol is absorbed (Miettinen et
al 1989). Plant sterols such as sitosterol, stigmasterol, and campesterol are the major
sterols of  plants. All higher plants are able to synthesize these sterols from acetyl CoA
via squalene,  and via cycloartenol instead of via lanosterol. Campesterol (C-28 sterol)
and sitosterol (C-29 sterol) differ from cholesterol (C-27 sterol) by the presence of an
extra methyl or ethyl group at C-24. In humans, plant sterols are not synthesized.
Vegetable oils and nuts are the most important dietary sources of plant sterols
(Weihrauch and Gardner 1978). In western countries, the daily plant sterol intake is 100
to 300 mg (Miettinen et al 1989). Plant stanols, on the other hand, are saturated
derivatives of plant sterols, and are virtually unabsorbable (Sugano et al 1977), whereas
5 to 10% of plant sterols are absorbed from the intestine (Subbiah 1973, Heinemann et
al 1993). Serum levels of plant sterols and cholestanol are also regulated by their biliary
secretion (Salen et al 1970, Miettinen et al 1989). In a normal population, fasting serum
levels of plant sterols and cholestanol reflect cholesterol absorption efficiency (Tilvis and
Miettinen 1986, Miettinen et al 1989, Miettinen et al 1990). 
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2.1.4.  Cholesterol elimination
    Cholesterol output from the body occurs mainly in the liver, either directly as free
cholesterol or after being catabolized to bile acids. The nonhepatic pathways of
cholesterol removal are via production of steroid hormones and desquamation of
epithelial cells. Under normal conditions, steroid hormone production is less than 10%
of total daily fecal steroid output.
    
2.1.4.1.  Neutral steroid output
  Cholesterol is secreted by the hepatocytes via the canalicular membrane into bile and
partly eliminated unchanged in the feces. Other major neutral steroids in human feces are
coprostanol and phytosterols, but coprostanone, cholestanol, and cholesterol precursors
(lanosterol, dihydrolanosterol, desmosterol, and lathosterols) also appear in small
amounts (Miettinen et al 1965, Ferezou et al 1978, Miettinen 1982b). Coprostanol and
coprostanone are formed from cholesterol by colonic bacteria (Rosenfeld et al 1954).
Except for phytosterols and unabsorbed dietary cholesterol, other neutral steroids arise
from a transfer of the plasma and hepatic cholesterol pool into bile (biliary excretion) and
from an intestinal flux of cholesterol synthesized by enterocytes (external secretion). In
man, the fecal neutral steroids derived from biliary excretion and external secretion,
amount to about 67% and 13%, respectively (Ferezou et al 1981).
2.1.4.2.  Bile acid synthesis
    Approximately 40% of total body cholesterol removal takes place by bile acid
synthesis. Cholesterol 7 -hydroxylase and sterol 27-hydroxylase are the rate-limiting
enzymes in the bile acid synthesis pathway (Shefer et al 1970, Björkhem 1992). The bile
acid synthesis rate in humans, as measured by the CO  output technique, is about 105014 2
µmol/day, representing a daily conversion of 400 to 500 mg of cholesterol (Duane et al
1983). Cholic acid (3, 7, 12-trihydroxy-5-cholanoic acid) and chenodioxycholic
acid (3, 7 -dihydroxy-5-cholanoic acid ) are synthesized in the liver and are referred
to as primary bile acids. Once formed, they are conjugated with taurine and glycine, and
their canalicular secretion into bile is coupled with that of cholesterol. During intestinal
transit, cholic acid and chenodeoxycholic acid are metabolized by colonic bacterial
enzymes to deoxycholic acid (3, 12-dihydroxy-5-cholanoic acid) and lithocholic acid
(3-hydroxy-5-cholanoic acid). Human bile consists of 30 to 40% cholic acid, 30 to
40% chenodeoxycholic acid, 20 to 25% deoxycholic acid, and 1 to 2% lithocholic acid.
Bile acids facilitate the excretion of biliary lipids, and because of detergent action, also
mediate intestinal absorption of lipids and fat-soluble vitamins. Bile acid absorption takes
place against a concentration gradient in the ileum (Playoust and Isselbacher 1964), and
about 95% of the excreted bile salts is reabsorbed. Fecal excretion of bile acids and
neutral steroids is associated with dietary intake of cholesterol and by dietary fatty acid
composition (Table 2). In general, consumption of diets rich in cholesterol, plant sterols,
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fibers, and PUFA, in contrast to saturated fatty acid (SAFA)-rich diets, increases fecal
excretion of bile acids and neutral steroids.   
Table 2.   Diet and fecal steroid excretion in humans  
                                                                                                                                             
Dietary variable                  Fecal bile acid                                      Fecal neutral steroids  
                                                                                                                                                       
Fat                                    Cummings et al 1978                         --- 
PUFA                               Connor et al 1969, Nestel et al    Connor et al 1969, Nestel et al    
1973, Grundy 1975              1973, Grundy 1975
SAFA                               Connor et al 1969                         Connor et al 1969                       
                                 Glatz and Katan 1993                 Glatz and Katan 1993
Cholesterol                       Gylling and Miettinen 1992,        Gylling and Miettinen 1992,
                                            Lin and Connor 1980,              Duane 1993
 Duane 1993
Carbohydrate                 / Schreibman and Ahrens 1976   / Schreibman and Ahrens 1976
Fiber                                 Kesäniemi et al 1990                    Kesäniemi et al 1990  
    Pectin                            Miettinen and Tarpila 1977,         Kay and Truswell 1977a
                                            Kay and Truswell 1977a            /  Miettinen and Tarpila 1977
    Oat bran                        Kirby et al 1981                           Kirby et al 1981
    Wheat bran                    Kay and Truswell 1977b             Kay and Truswell 1977b
Plant sterols and stanols /  Grundy et al 1969                      Grundy et al 1969, Lees et al     
                                                                                                     1977, Vanhanen et al 1994
                                                                                                                                                      
 ,  : significant change; , : nonsignificant change; : no change.
2.2.  Coronary artery disease and risk factors
2.2.1.  Women and CAD risk factors
Menopause, lipids, and CAD
       Coronary artery disease is the major cause of death in women (Mosca et al 1997).
Although lower CAD morbidity and mortality rates occur in women than in men of
similar ages (Lerner and Kannel 1986, Rich-Edwards et al 1995, McGovern et al 1996,
Njolstad et al 1996), their CAD mortality rate is higher than in males after age 83 (Mosca
et al 1997). The prevalence of CAD in women increases after the menopause and loss of
endogenous estrogens (Kannel et al 1976, Hu et al 1999). Conversely, the mortality rate
from CAD appears to increase constantly in women throughout life, not accelerated by
the onset of menopause (Lerner and Kannel 1986, Barrett-Connor 1997). Thus, ageing
is a significant risk factor for CAD in women as in men.  
        Several epidemiologic studies confirm lipid and lipoprotein differences between
pre- and postmenopausal women. Following spontaneous menopause, healthy women
have higher levels of total, LDL, and VLDL-cholesterol, total triglycerides, apo B-100,
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and lipoprotein(a), while their HDL-cholesterol level remains unchanged (Brown et al
1993a, Schaefer et al 1994). Furthermore, postmenopausal women have smaller LDL
particles than do premenopausal women (Campos et al 1988, Schaefer et al 1994).
Estrogen replacement increases HDL cholesterol, apo A-I, and triglyceride levels, but
lowers LDL cholesterol and apo B-100 concentrations (Walsh et al 1991). Progestins in
combination with estrogen attenuate the beneficial lipid effects of estrogen (Miller et al
1991). Overall, combined hormone replacement therapy (HRT) favorably alters the
serum lipid profile (Brown et al 1993a, Saure et al 1993). HRT reduces major coronary
events (Bush et al 1987, Grodstein et al 1996, Varas-Lorenzo et al 2000), but
contradictory results have also been reported (Hulley et al 1998, Barrett-Connor and
Stuenkel 1999).
Conventional risk factors in CAD women
    Risk factors for CAD in the female population have been explored in some earlier
studies (Eaker et al 1993, Rich-Edwards et al 1995, Jousilahti et al 1999). Ageing (Lerner
and Kannel 1986, Barrett-Connor 1997) and parental history of CAD (Myers et al 1990,
Pohjola-Sintonen et al 1998) are non-modifiable risk factors for CAD. Of the modifiable
risk factors, elevated serum and LDL cholesterol levels and total / HDL cholesterol ratio
are directly related to annual incidence of and mortality rate from CAD (Stamler et al
1986, Kannel 1987, Verschuren et al 1995, Jousilahti et al 1999), and the total / HDL
cholesterol ratio is an important risk factor for CAD, especially in women (Simons 1986,
Romm et al 1991). Low HDL cholesterol levels are often associated with high serum
triglyceride levels, but both are independently associated with risk for CAD in women
(Lerner and Kannel 1986, Ettinger et al 1992, Austin et al 1998, Jousilahti et al 1999). It
has been shown that in healthy women, high LDL cholesterol and low HDL cholesterol
levels measured premenopausally were significant predictors of coronary calcification
after menopause (Kuller et al 1999).
   Obesity, indicated by body mass index (BMI) (Manson et al 1990, Calle et al 1999),
centralized body fat, indicated by waist-to-hip ratio (Larsson et al 1992), diabetes (Lerner
and Kannel 1986, Kannel 1987, Mosca et al 1999), high blood pressure levels (Njolstad
et al 1996, Jousilahti et al 1999), and low physical activity (Kushi et al 1997) are
associated with increased risk for CAD in women. Smoking, a key behavioral risk factor
for CAD, is associated with a high incidence rate of CAD in women (Willett et al 1987,
Njolstad et al 1996, Jousilahti et al 1999), and cessation of smoking prevents secondary
coronary events in women (Wilson et al 2000). In addition, among women aged 45 to 64,
psychosocial variables such as tension and anxiety, loneliness, low educational level, and
low financial status predicted major coronary events (Eaker et al 1992).
2.2.2.  Cholesterol metabolism and CAD
    Only a limited number of studies exist that evaluate the association between
cholesterol metabolism and atherosclerosis. Ileal bypass surgery, which reduces serum
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cholesterol by causing bile acid malabsorption followed by enhanced cholesterol
synthesis, has reduced coronary morbidity and mortality (Buchwald et al 1998). In a
limited number of coronary patients (n=9) with primary hypercholesterolemia, but not in
those with normocholesterolemia, cholesterol synthesis appeared to be lower than that of
controls (Miettinen 1971a). Low bile acid synthesis is associated with the prevalence of
CAD in male subjects with familial hypercholesterolemia (Simonen and Miettinen 1987),
and also associated with poor prognosis after a 15-year follow-up (Miettinen and Gylling
1988). It has also been shown that coronary patients appeared to have lower fecal
elimination of bile acids than do normal subjects (Charach et al 1998). In addition, type
II diabetic subjects with CAD have higher cholesterol absorption efficiency than do non-
CAD diabetic controls (Gylling and Miettinen 1996a). Recent studies have suggested that
in coronary subjects with primary moderate hypercholesterolemia treated with
simvastatin, low synthesis and high absorption efficiency of cholesterol predicts recurrent
coronary events (Miettinen et al 1998). Thus, cholesterol metabolism may play a major
role in the development of atherosclerosis. However, whether cholesterol metabolic
variables are associated with the prevalence of CAD in postmenopausal women has
remained unknown.
      Squalene has been identified in arterial tissues (Garbuzov et al 1965, Liu et al 1976)
and in human atherosclerotic plaques (1 mg squalene/g wet weight of plaque tissue)
(Brooks et al 1966). In one study, only a very small amount (1.3 µg/g wet weight) of
squalene was found in the plaques; however, the squalene content was three times as
high as that of the normal aorta (Lewis 1975). Additionally, human arterial segments
(St.Clair et al 1968) and atherosclerotic lesions (Chobanian 1968) have the ability in vitro
to produce squalene. Whether serum squalene concentrations are altered in CAD is
unknown.
2.2.3.  Postprandial lipoproteinemia and CAD
     A considerable portion of human life is spent in the postprandial state, and
pronounced postprandial lipoproteinemia has been proposed to be an atherogenic factor
(Moreton 1947, Zilversmit 1979). Temporary accumulation of chylomicrons and
chylomicron remnants during the postprandial state may lead to lipid deposition in
arterial intima (Stender and Zilversmit 1982), and in macrophages (Floren and Chait
1981, Fujioka et al 1998), which become foam cells in atherosclerotic lesions. Several
studies have documented the fact that men with CAD have pronounced postprandial
lipoproteinemia in comparison with that of healthy controls (Barritt 1956, Simons et al
1987, Groot et al 1991, Karpe et al 1993a, Ginsberg et al 1995). In male subjects,
postprandial triglyceride concentrations highly predict the presence or absence of CAD
(Patsch et al 1992), and small chylomicron remnants of S  20 to 60 are associated withf
the progression of coronary lesions (Karpe et al 1994). Very few postprandial studies
focus on women with CAD, even though men and women are postulated to have
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differences in postprandial lipoprotein metabolism. Women do not achieve as high
postprandial retinyl ester concentrations to oral vitamin A-fat-loads as men (Johnson et
al 1992). Coronary patients, including female subjects, had higher postprandial responses
in lipoproteins of d>1.006 g/ml density than did healthy subjects (Weintraub et al 1996),
and the CAD women had higher postprandial concentrations of IDL than did women
with valvular heart disease serving as controls (Meyer et al 1996). On the other hand, in
another study, two dozen women with angina only and without a history of myocardial
infarction had no accumulation of postprandial lipoproteins (Ginsberg et al 1995).
Accordingly, whether pronounced postprandial lipemia is associated with coronary
atherosclerosis in women as in men seems not to be completely settled. 
      Postprandial lipoproteins might be atherogenic since chylomicrons can penetrate
arterial tissue after conversion to their remnants. Chylomicron remnants are taken up by
the native LDL receptor in cultured human arterial smooth muscle cells (Floren et al
1981) and macrophages (Floren and Chait 1981, Fujioka et al 1998). In the absence of
LDL-receptors, LRP mediates chylomicron remnant uptake by mouse peritoneal
macrophages (Fujioka et al 1998). Furthermore, apo B-48 of chylomicrons binds
specifically to a membrane-binding protein (apo B-48 receptor) in human monocytes and
macrophages (Gianturco et al 1998, Brown et al 2000). The receptor-mediated uptake of
chylomicron remnants leads to lipid accumulation and to the formation of macrophage-
derived foam cells in eruptive xanthomas in diabetic patients (Parker et al 1970) and of
atherosclerotic lesions in mouse (Gianturco and Bradley 1999). In human atherosclerotic
plaques, apo B-100 (Hoff et al 1975) and apo B-100-containing TGRL particles have
been isolated (Rapp et al 1994), but apo B-48 thus far has not been identified in these
lesions. Recently, apo B-48-receptor expression has been identified in macrophages and
foam cells within human atherosclerotic lesions (Brown et al 2000). In addition to this
possible direct mechanism, it can be proposed that the atherogenicity of plasma
chylomicron remnants are indirectly related either to coronary endothelial dysfunction
(Kugiyama et al 1998) or to atherogenic metabolism of other lipoproteins, such as altered
VLDL lipid composition (Björkegren et al 1997), predominance of small dense LDL,
triglyceride accumulation of dense LDL (Karpe et al 1993b), increased susceptibility to
LDL oxidation (Lechleitner et al 1994), and decreased serum HDL cholesterol levels
(Karpe et al 1993a).  
2.3.  Hypolipidemic treatment 
2.3.1.  Statin treatment 
    Serum cholesterol levels can be reduced by inhibiting most of the enzymes (Figs.1 &
2) involved in cholesterol biosynthesis. In animals, squalene synthase inhibitors, such as
squalestatin (zaragozic acids) (Baxter et al 1992) and some phosphonates (ER-28448 and
ER-27856) (Hiyoshi et al 2000), reduced hepatic cholesterol synthesis and serum
cholesterol level. Triparanol inhibits sterol  isomerase and sterol  -reductase8->7 24
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(Popjak et al 1989), but it has side effects (Laughlin and Carey 1962, Wong et al 1966).
HMG CoA reductase inhibitors, statins, are originally fungal metabolites, and the earliest
statin, compactin, was discovered from Penicillium citrinum in the mid 1970s (Endo
1992). Today, at least 6 statins, including synthetic statins, are widely used to lower
serum cholesterol levels. 
    Inhibition of cholesterol biosynthesis by statins increases hepatic LDL-receptor
expression, which in turn increases the clearance of LDL (Kovanen et al 1981,
Malmendier et al 1989, Berglund et al 1998). However, in some studies, fractional
catabolic rate of LDL apo B-100 remained unchanged (Cuchel et al 1997) or was reduced
(Vega et al 1988) during statin therapy. Statins were able to reduce production rate of apo
B-100 of VLDL (Watts et al 1995) and of LDL (Gylling and Miettinen 1996b, Cuchel et
al 1997, Berglund et al 1998) or had no significant effect on VLDL-apo B-100
production (Cuchel et al 1997).  
      Serum cholesterol precursors are reduced during statin treatment (Uusitupa et al
1992, Vanhanen et al 1992, Miettinen et al 1992a, Gylling and Miettinen 1996b),
substantiating a reduction in cholesterol synthesis (Miettinen 1991, Vanhanen et al 1992,
Duane 1993, Gylling et al 1995a, Cuchel et al 1997), but few studies showed an
inconsistent reduction in cholesterol synthesis (Grundy  and Bilheimer 1984, Goldberg
et al 1990, Vanhanen and Miettinen 1995). Cholesterol absorption efficiency is also
reduced by statin treatment in patients with familial hypercholesterolemia (Miettinen
1991, Vanhanen et al 1992), but not in mildly hypercholesterolemic patients (Duane
1993, Vanhanen and Miettinen 1995). In addition, reduced bile acid synthesis (Duane
1993, Loria et al 1994, Hanson  and Duane 1994) and reduced (Hanson and Duane 1994)
or unchanged (Loria et al 1994) biliary secretion of cholesterol has been reported during
statin treatment.  
2.3.2.  Treatment with plant sterols and stanols
     Since cholesterol absorption efficiency is also essential in regulating cholesterol
homeostasis, one approach in treating hypercholesterolemia is to inhibit cholesterol
absorption. Plant sterols (Grundy et al 1969), sucrose polyester (Crouse and Grundy
1979), neomycin (Kesäniemi and Grundy 1984, Gylling and Miettinen 1995), and
clofibrate (Grundy et al 1972) all reduce cholesterol absorption. The cholesterol-lowering
effect of dietary plant sterols has been reported since the 1950s (Pollak 1953, Farquhar
et al 1956, Grundy et al 1969, Lees et al 1977, Jones et al 1998). Plant sterols in humans
are solely of exogenous origin. Although they are only 5 to 10% absorbed,  after plant
sterol intake, serum plant sterol concentrations eventually increase. In fact, campesterol-
rich soybean sterols and sitosterol-rich tall oil sterol suspension increase serum
campesterol and sitosterol concentrations, respectively (Lees et al 1977).
     Plant stanols are less efficiently absorbed than plant sterols. In 1994, plant stanol ester
was introduced in margarine, and since then its hypocholesterolemic effect has been
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reported in normolipidemic adults (Niinikoski et al 1997), mildly hypercholesterolemic
patients (Miettinen et al 1995, Nguyen et al 1999, Gylling et al 1999),
hypercholesterolemic NIDDM patients (Gylling and Miettinen 1996b), and in familial
hypercholesterolemic children (Gylling et al 1995b) and adults (Vuorio et al 2000). The
dose-response relationship of plant stanol ester has been evaluated: about 9% and 11%
reductions in serum and in LDL cholesterol levels were achieved by a daily intake of 1.8
g, whereas 10% and 14% reductions occurred respectively at 2.6 g/day (Miettinen et al
1995). In addition to cholesterol-lowering, stanol esters reduced LDL apo B-100 as well
as the transport rate for LDL apo B-100 (Gylling and Miettinen 1996b). In combination
with statins, plant stanol esters show an additive effect in lowering serum cholesterol
level (Gylling and Miettinen 1996b, Vuorio et al 2000).  
        Plant stanols reduce cholesterol absorption by up to 68% (Vanhanen et al 1994,
Gylling and Miettinen 1996b, Normen et al 2000). An increase in serum cholesterol
precursors and fecal steroids suggests that a compensatory increase in cholesterol
synthesis occurs following inhibition of cholesterol absorption by sitostanol ester
treatment (Vanhanen et al 1994, Nguyen et al 1999, Gylling et al 1999). 
2.3.3.  Hypolipidemic treatment and coronary events
        Guidelines have been reported for cholesterol-lowering therapy in both high-risk
primary prevention and secondary prevention of CAD (Expert Panel on Detection,
Evaluation, and Treatment of High Blood Cholesterol in Adults 1993). Accordingly,
LDL cholesterol levels should be reduced to <3.4 mmol/l (130 mg/dl) in the non-CAD
population with elevated LDL cholesterol levels, and to <2.6 mmol/l (100 mg/dl) in CAD
patients. 
     Benefits of cholesterol-lowering therapy in both primary and secondary prevention of
CAD have been documented in many studies (LaRosa et al 1999). In primary prevention
trials, treatment of clofibrate (Committee of principal investigators 1978), gemfibrozil
(Frick et al 1987), resins (Lipid Research Clinics Program 1984), and pravastatin
(Shepherd et al 1995) all reduced major coronary events. Women were included in the
Air Force / Texas Coronary Atherosclerosis Prevention Study, in which lovastatin
treatment reduced major coronary events by 37% (Downs et al 1998). In secondary
prevention trials with nicotinic acid (Canner et al 1986), simvastatin (Scandinavian
Simvastatin Survival Study Group 1994), and pravastatin (Sacks et al 1996, The Long-
Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group 1998),
reduction of serum and LDL cholesterol was associated with a decline in CAD events,
and this reduction was found in one trial to be greater in women than in men despite
similar reductions in lipid levels for both groups (Lewis et al 1998).
    Mechanisms responsible for the beneficial effect of cholesterol-lowering have been
suggested: Cholesterol reduction can retard the progression of coronary atherosclerosis
and can cause atherosclerosis to regress (Brown et al 1993b). Furthermore, animal
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models suggest that hypolipidemic treatment not only lowers extracellular lipid deposits
in plaques, but also raises the collagen content in coronary lesions, hence increasing
plaque stability (Shiomi et al 1995). Statin therapy can improve coronary vasomotor
responses in patients with CAD (Treasure et al 1995). 
2.3.4.  Hypolipidemic treatment and serum squalene 
     Inducing changes in cholesterol synthesis should induce corresponding alterations in
serum squalene levels. Administration of guar gum (Miettinen and Tarpila 1989), or
charcoal (Neuvonen et al 1989), or colestipol (Nestel and Kudchodkar 1975), or of
cholestyramine alone (Liu et al 1976) or with acipimox (a nicotinic acid analogue)
(Gylling et al 1989), appeared in each case to enhance cholesterol synthesis; accordingly,
serum squalene levels were also elevated. Clofibrate and gemfibrozil significantly reduce
serum squalene levels (Nestel and Kudchodkar 1975, Miettinen et al 1992a), whereas
statins, which reduce cholesterol synthesis, inconsistently alter squalene serum levels.
Simvastatin treatment, in contrast to that of pravastatin (Vanhanen and Miettinen 1995),
failed to lower serum squalene ratios, but did so after gemfibrozil administration
(Miettinen et al 1992a). Lovastatin treatment simultaneously reduced cholesterol
synthesis and the ratio of serum squalene to cholesterol in patients with type III
hyperlipoproteinemia (Gylling et al 1995a), but reduced only the serum levels in severe
hypercholesterolemic patients (Uusitupa et al 1992). Fasting reduced synthesis of
squalene and cholesterol in human adipose tissue (Tilvis and Miettinen 1979), whereas
hypocaloric diets reduced serum squalene levels (Liu et al 1976).
    Sitostanol ester-induced or neomycin-induced cholesterol malabsorption enhances
cholesterol synthesis, and should have had the effect of increasing serum squalene. But
the serum levels were not altered by sitostanol ester treatment either in diabetic patients
(Gylling and Miettinen 1996b), or in hypercholesterolemic subjects who were on statin
(Vanhanen 1994) or off statin (Vanhanen et al 1994). Neither did neomycin alter serum
squalene in pravastatin-treated familial hypercholesterolemic patients, despite its effects
of increasing serum cholestenol and lathosterol (Vanhanen 1994). Cholesterol synthesis
stimulated by both bile acid and fat malabsorption in patients with gut resection was
associated with an increase in serum squalene (Färkkilä et al 1988). But in celiac
patients, a cholesterol malabsorption-induced increase in cholesterol synthesis was
associated only with high serum methyl sterol concentrations (Vuoristo and Miettinen
1986). In these patients, gluten-free diets reduced the level of serum cholesterol
precursors, but not that of squalene. Cholesterol malabsorption in patients with
pancreatic insufficiency was associated both with enhanced cholesterol synthesis and
with fecal squalene output, but not with serum squalene values (Vuoristo et al 1992).
Taken together, serum squalene levels, in contrast to that of other cholesterol precursors,
are inconsistently altered by changes in cholesterol metabolism.  
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3.  AIMS OF THE STUDY
      Even though CAD is a major cause of mortality in women, etiological factors for
CAD have been studied less extensively in women than in men. Elevated serum
cholesterol level has been established as a strong risk factor for CAD, but the association
of CAD with cholesterol metabolism or postprandial lipoprotein metabolism has not been
well evaluated in women. Squalene is a nonsterol intermediate of cholesterol
biosynthesis. Its serum level, in contrast to that of cholesterol precursor sterols, is
inconsistently associated with cholesterol synthesis rate. Squalene has been identified in
human atherosclerotic plaques, but its fasting and postprandial levels in serum and
lipoproteins, and its metabolism in CAD have not been investigated in women. In
addition, it is not yet known how reducing serum cholesterol level by inhibiting
cholesterol absorption and synthesis may affect serum squalene in female CAD patients.
The objectives of the present study were
1. To investigate squalene levels in serum and lipoproteins and their association with   
    CAD in postmenopausal women. 
2. To evaluate whether postprandial squalene and lipoprotein clearance are altered in   
    CAD women.
3. To investigate whether any variables of cholesterol metabolism are associated with  
    CAD and lipid risk factors in women.
4. To study how effectively cholesterol malabsorption (by stanol ester) alone or in        
    combination with synthesis-inhibition of cholesterol (statins) alters serum squalene  
    and lipid levels in relation to variables of  cholesterol metabolism in CAD women.
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4.  SUBJECTS AND METHODS
4.1.  Subjects and designs 
    Postmenopausal women, aged 50 to 55, who had been successfully treated for CAD at
the University Central Hospital of Helsinki from 1988 to 1996 were recruited to the study
(n=48). CAD was verified by coronary angiography as at least 50% occlusion in two
coronary vessels. Age-matched postmenopausal women were randomly chosen from the
population registry of Helsinki as controls (n=61). The controls were free of chest pain
and dyspnea, and their electrocardiograms (ECG) were normal. Postmenopause was
defined by amenorrhoea and elevated serum follicle-stimulating hormone level (FSH>
30 U/l). Subjects on hypolipidemic medication or with severe heart, liver, thyroid, or
digestive tract diseases or malignancies or diabetes mellitus were excluded.
    All subjects underwent physical examinations. History of CAD in family members,
smoking, and medication including HRT were recorded, and weight, height, and blood
pressure measured. Blood samples were collected in the morning following a 12-h fast,
and they were analyzed for lipids and lipoprotein lipids, apo B-100, apo E phenotyping,
squalene and noncholesterol sterols, hemoglobin, leukocytes, erythrocyte sedimentation
rate, thyrotropin, FSH, sex-hormone binding globulin (SHBG), insulin, glycosylated
hemoglobin A1c (GHbA1c), and glucose.  
     All subjects volunteered for the study and gave the informed consent. The study
protocol followed the ethical principles of the Declaration of Helsinki and was approved
by the Ethics Committee of the Second Department of Medicine, University of Helsinki.
4.1.1.  Studies I and II
     For these studies, volunteers were 25 CAD women and 30 healthy controls. Of the
cases, 12 had suffered from myocardial infarction, 9 had undergone coronary artery
bypass surgery, and 13 percutaneous transluminal angioplasty, all at least 6 months
before entry to the study. None of the cases and controls were extremely obese (BMI <30
kg/m²). Beta-blocking agents were used by 15 patients and 3 controls (P<0.001), an
angiotensin converting enzyme inhibitor by one case and 2 controls (P=NS), and thiazide
diuretics by 2 control women. None of the CAD women was on hormone replacement,
whereas among the controls, 2 used transdermal estrogen, 8 peroral combined estrogen
and progestin and 2 progestin alone.
Fasting squalene and lipids of serum and lipoproteins (Study I)      
    Fasting blood samples were separated for chylomicrons, VLDL, and VLDL bottom
(d>1.006 lipoproteins) and analyzed for cholesterol, triglycerides, and squalene.
Postprandial squalene and lipoprotein metabolism (Study II)       
   All the subjects received an oral vitamin A-squalene fat-tolerance test. After a 12-h
fast, a blood sample was drawn for baseline values, after which the participants were
given a morning test meal containing 2 dl of 38% cream, an egg yolk, 345 000 IU of
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vitamin A, and 0.5 g of squalene. This meal consisted of 90 g of fat, 432 mg of
cholesterol for 1200 kcal of energy. During the 24-h period following the meal, the
subjects were fasting except for a routine hospital meal at 9 hours. Blood samples were
taken at 3, 4, 6, 9, 12, and 24 hours. Chylomicrons, VLDL (chylomicron remnants), and
VLDL bottom were separated from these blood samples, and cholesterol, triglycerides,
retinyl palmitate, squalene, and apo B-48 were measured.
     
4.1.2.  Risk factors for CAD: Impact of serum squalene and noncholesterol sterols
           (Study III)   
     For the study, 48 consecutive CAD patients and 61 control women volunteered; 29
coronary patients had suffered from myocardial infarction, and the rest had had stable
angina pectoris without infarction; 26 patients had been treated with percutaneous
transluminal angioplasty and 21 with bypass surgery, all at least 6 months earlier before
entry to the study. Beta-blockers were consumed by 34 of the cases and 6 of the control
women (P<0.001), calcium blockers by 16 and 4, respectively (P<0.01), diuretics by 3
and 5 (P=NS), and angiotensin-converting enzyme inhibitors by 3 and 5 (P=NS). Of the
CAD women, 18, and of the healthy women 28 used exogenous hormone substitution
(P=NS).    
4.1.3.  Squalene, cholesterol metabolism, and CAD (Study IV)    
   For the cholesterol metabolic studies, 29 cases and 20 controls volunteered; 20 of the
cases had suffered an acute myocardial infarction at least 6 months earlier. No subjects
were on HRT. All were advised to continue their normal diets, and each kept a 7-day
dietary recall. Feces collected for the previous 3 days were analyzed for squalene,
cholesterol precursors, neutral steroids, and bile acids. Baseline measurements were
performed on a blood sample drawn after a 12-h overnight fast.
4.1.4.  Sitostanol ester margarine with and without statin in CAD women (Study V)
     The effect of sitostanol ester dissolved in rapeseed oil margarine was investigated in
22 volunteer CAD patients. Among them, 11 had been treated with percutaneous
transluminal coronary angioplasty and 8 with coronary artery bypass at least 3 months
earlier. In addition, sitostanol ester margarine had been administered to 10 patients who
had been treated with simvastatin 10 to 20 mg for more than a year in the Lipid Clinics
of the University Central Hospital to investigate the combined effect of cholesterol
malabsorption and inhibited synthesis.
    The patients were advised to stay on their normal home diets for a month. The women
without statin treatment were randomized to replace 21 g of their daily fat intake by
rapeseed oil margarine with (n=11) or without (n=11) sitostanol ester (3 g sitostanol/21
g margarine) for the next 7-week period. This was followed by switching margarines for
the next 7 weeks. The women on statin treatment also replaced 21 g of their daily fat 
intake by sitostanol ester margarine for a 12-week period. The 21 g of margarine was
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divided into three doses and consumed with their 3 major meals. Serum and lipoprotein
lipids and serum squalene and noncholesterol sterols were analyzed in 2 fasting blood
samples at the beginning and the end of each margarine treatment period. Fecal output of
squalene and cholesterol precursors and cholesterol metabolism were determined at
baseline: before the margarine treatment and then at the end of both 7-week margarine
treatment periods, but not during the statin and combined treatments.  
    
4.2.  Methods
4.2.1.  Baseline measurements
     Subjects were advised to continue their normal diets, and dietary fat and cholesterol
were calculated from 7-day dietary recalls (Knuts et al 1997). Blood hemoglobin and
leukocytes were measured by electronic blood cell counter, erythrocyte sedimentation
rate by the Westergren method,  serum thyrotropin by immunoluminometric assay
(Taimela et al 1994), serum FSH by immunoluminometric assay (Price and Bennett
1995), serum SHBG by immunofluorometric assay (Rosner 1972), serum total insulin by
radioimmunoassay (Gennaro and Van Norman 1975), blood GHbA1c by high-
performance liquid chromatography (HPLC) (Ashby et al 1985), and blood glucose
enzymatically (hexokinase) with commercial kit (Boehringer Diagnostica, Germany).
4.2.2.  Lipids and apolipoproteins
  Cholesterol and triglycerides were measured enzymatically with commercial kits
(Boehringer Diagnostica, Germany). HDL cholesterol was measured after precipitation
of apo B-100-containing lipoproteins with manganous chloride and heparin (Burstein et
al 1970). LDL cholesterol was calculated by Friedewald formula (Friedewald et al 1972),
provided that serum triglycerides were below 3 mmol/l. Apo B-100 was assayed
immunoturbidimetrically with anti-human antiserum by use of a commercial kit (Orion
Diagnostica, Finland). Apo E phenotypes were determined by isoelectric focusing
(Havekes et al 1987).
4.2.3.  Lipoprotein fractionation
   Lipoproteins from fasting sera were separated by ultracentrifugation in a fixed-angle
Ti 50.4 rotor (Beckman Instruments ®) as follows: VLDL: <1.006 g/ml, IDL: 1.006-
1.019 g/ml, LDL: 1.019-1.063 g/ml, and HDL: 1.063-1.210 g/ml. Chylomicrons, VLDL
(chylomicron remnants), and TGRL were separated from postprandial samples. For this
purpose, 7.2 ml of plasma was overlayered with a salt solution of density 1.006 g/ml and
centrifuged at 18 000 rpm for 30 minutes. Chylomicrons were isolated by aspiration of
the top 3.6 ml. The infranatant was then mixed with 1.006 g/ml salt solution and
centrifuged at 35 000 rpm for 18 hours to separate VLDL (chylomicron remnants).
Another aliquot of 3 to 3.5 ml plasma was overlayered with a salt solution of density
1.006 g/ml and ultracentrifuged at 35 000 rpm for 18 hours. The TGRL fraction was
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recovered in the top 0.5 ml. 
4.2.4.  Quantification of squalene and noncholesterol sterols
    Cholesterol, squalene, and noncholesterol sterols were measured by gas-liquid
chromatography (GLC) as described earlier (Miettinen and Koivisto 1983, Miettinen
1988a). Briefly, 5 -cholestane was added to serum samples as an internal standard, after
which the samples were saponified with 95% ethanol and KOH. Nonsaponified lipids
were extracted by hexane, and squalene and noncholesterol sterols were quantitated on
a 50 m-long capillary column (Hewlett Packard® Ultra I) after trimethylsilylation. An
average of 2 baseline squalene and noncholesterol sterol concentrations was used in this
study. Serum squalene and noncholesterol sterols are carried in serum by lipoproteins,
mainly by LDL. Therefore, squalene and noncholesterol sterol values were expressed as
ratios to cholesterol to minimize any interindividual variation in lipoprotein levels. In this
text, the squalene and noncholesterol sterol ratios are also expressed as squalene and
noncholesterol sterols. Concentrations are noted when relevant.     
4.2.5.  Quantification of retinyl palmitate
    Retinyl palmitate was measured in chylomicrons, VLDL and d>1.006 g/ml
lipoproteins by HPLC by the method described by Ruotolo  and coworkers (1992).
During all the procedures, samples were protected from light to avoid denaturing retinyl
palmitate. A solvent mixture of hexane (82% of v), n-butyl chloride (14% of v),
acetonitrile (4% of v), and 10 to 50 µl acetic acid was used as the mobile phase buffer.
Lipoprotein samples of 100 to 500 µl were added with 500 µl of methanol and 500 µl of
mobile phase buffer for lipid extraction. Retinyl acetate (20 ng /100 ml mobile phase
buffer) was then added as the internal standard, and the final volume was adjusted to 1.7
ml with normal saline. The solutions were mixed and centrifuged at 350 g for 15 min at
room temperature. The supernate was removed carefully and dried under nitrogen. Lipids
were then dissolved in buffer and injected into a HPLC system with a normal phase
HPLC column (Supelco sil LC-S1 5 µm, 25 cm x 4.6 m). Flow rate was maintained at
constant 2 ml/min, and retinyl acetate (peaking at 1.8 min), retinyl palmitate (peaking at
2.1 min), and retinol (peaking at about 4 min) were detected by a fixed wave-length
detector with a 330 nm filter. The peaks were verified with commercially available
retinyl ester and retinol compounds. Retinyl palmitate was quantitated from peak areas
of retinyl acetate and palmitate and the known amount of retinyl acetate.   
 
4.2.6.  Assay of apolipoprotein B-48
     The method described earlier (Karpe and Hamsten 1994) was modified to assess apo
B-48 in the TGRL fraction at baseline and at 4, 6, 9, and 24 hours postprandially.
Isolated LDL apo B-100 was used as a standard for apo B-48. Lipoprotein preparations
were dialyzed overnight at 4C against  0.15 mol/l NaCl, in 1 mmol/l EDTA, pH 7.4.
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The protein mass of the LDL fraction was determined by the Lowry procedure with
bovine serum albumin (Sigma, catalogue no.A 9418) as the standard (Lowry et al 1951).
The dialyzed LDL and TGRL fractions, containing 60 to 200 µg protein, were
delipidated with ice-cold ethanol:diethyl ether  and centrifuged to precipitate apo’s
(Scanu and Edelstein 1971). The protein sediment was then resolubilized in sample
buffer containing 0.5 mol/l Tris, 0.15 mol/l sodium phosphate, 10% sodium dodecyl
sulphate, 87% glycerol, 1.12 g/ml 2-mercaptoethanol, and 0.05% bromophenol blue, and
denatured at 80C for 10 minutes. The apo B-100 standard (0.1-1 µg protein) and TGRL
fractions were applied to two 2 to 14% sodium dodecyl sulfate polyacrylamide gradient
gels in a Mini-Protean II vertical gel apparatus (BioRad ®) and were run simultaneously
at 90 V for 10 minutes and then 200 V for 60 minutes. The gels were stained with 0.04%
Coomassie blue G-250 and destained with 5% acetic acid. They were then scanned on a
CliniScan 2 densitometer (Helena Laboratories, USA), and the area under each peak was
integrated to achieve the related absorbance. The linear regression line between the
absorbance and the known LDL apo B-100 mass was used to calculate the apo B-48
concentration in the TGRL fraction. Apo B-100 was not measured in the TGRL fraction,
as it needs an extra gel-application of 10- to 20-fold diluted samples.
4.2.7.  Determination of cholesterol absorption efficiency and elimination
     Each subject consumed one capsule containing 0.1 µCi of [ C] cholesterol and 0.214
µCi of [ H] sitostanol 3 times daily with major meals during the 7-day dietary recording.3
Chromic oxide (Cr O ; 200 mg) was added to the capsule to evaluate fecal flow (Bolin2 3
et al 1952). Stools were collected during the last 3 days. Fecal squalene, neutral steroids,
and bile acids were measured by GLC as described earlier (Grundy et al 1965, Miettinen
et al 1965, Miettinen 1982b). Cholesterol absorption efficiency was calculated from the
difference between the dietary intake and fecal output of the [ C] cholesterol/14
[ H] sitostanol ratio (Crouse and Grundy 1978).3
4.2.8.  Data analyses
    Continuous values were expressed as mean ± SE. A P value less than 0.05 was
considered significant. Statistical analysis was performed with the BMDP statistical
computer software package. Differences between continuous variables were tested with
the two-tailed t-test or with the Mann-Whitney rank sum test, and between discrete
variables with the Chi-square test or with Fisher's exact probability test. Relationships
between continuous variables were assessed by Pearson or Spearman’s rank correlation
test and between categorical and continuous variables by Chi-square test. For the latter,
continuous variables were divided at their median point into two categories. Correlation
values refer to the entire study population; the values for cases or controls are noted when
relevant.
4.2.8.1.  Logistic regression analyses
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   Associations between CAD  and all other variables were first analyzed by univariate
logistic regression analysis and then by multivariate analysis, based on maximum
likelihood ratio. The presence of CAD  was included into the model as the dependent
variable, and family history of CAD  (yes or no), smoking (yes or no), and hypertension
(yes or no) as the independent categorical variables and others as the independent
continuous variables. Goodness of fit to the prediction was examined with the Hosmer-
Lemeshow test, and logistic function with the C.C. Brown test. In order to compare the
probability of the correct risk evaluation by serum squalene, by LDL cholesterol, by the
LDL-to-HDL cholesterol ratio, by non-HDL cholesterol, and by serum triglycerides,
receiver operating characteristic (ROC) curves were drawn by plotting the proportions of
true positive results (sensitivity) versus the proportions of false positive results (1-
specificity). Study subjects were ranked on their risk for CAD based on quartiles (Q) of
the factors, i.e., gradually increasing risk from Q1 to Q4. ROC curves were described by
area under the curve.
4.2.8.2.  Postprandial analyses
      Responses to the fat meal were characterized in terms of area under incremental
curve (AUIC) and incremental peak concentration (PIC). AUIC was calculated by the
trapezoidal method for 24-h curves. All postprandial triglyceride and apo B-48
concentrations were below baseline at 9 hours, so that 9-h AUICs were calculated for
these variables. PIC was the difference between the  baseline concentration and the
highest postprandial concentration observed. Group differences in postprandial
concentrations and 24-h curves were analyzed with analysis of variance (ANOVA) for
repeated measures. Analysis of covariance was used to calculate AUICs adjusted for
baseline variables.
  
4.2.8.3.  Analyses of cholesterol metabolism 
    Cholesterol synthesis is the difference between fecal output of steroids (neutral
steroids and bile acids) and dietary cholesterol. Total intestinal cholesterol flux = fecal
neutral steroids / (1 minus cholesterol absorption efficiency). Biliary cholesterol
secretion=intestinal cholesterol flux minus dietary cholesterol. The intestinal fluxes of
dietary, biliary, and total cholesterol were multiplied by cholesterol absorption efficiency
in order to calculate absorbed mass of dietary, biliary, and total cholesterol, respectively.
Cholesterol turnover was the total of cholesterol synthesis and absorbed dietary
cholesterol, and fecal endogenous neutral steroids was the difference between fecal
neutral steroids and unabsorbed dietary cholesterol.
5.  RESULTS
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5.1.  Baseline characteristics 
    The mean age of the study population was 53.40 ± 0.32 y. Both BMI and the frequency
of apo E phenotypes and exogenous hormone users were similar among the women with
and without CAD in all studies. Cholesterol in serum, chylomicrons, and VLDL were
comparable (Table 1 in Study I), but cholesterol in d>1.006 g/ml lipoproteins, especially
in LDL, was higher, and in HDL was lower in the cases than in the controls (Table 3).
Thus, the cases had significantly higher non-HDL cholesterol levels, LDL-to-HDL, and
total-to-HDL cholesterol ratios than did the controls. In Study IV, serum triglyceride
levels were significantly higher in the cases than in controls. Serum apo B-100
concentrations only tended to be higher, whereas basal apo B-48 levels were significantly
higher in the CAD women than in the healthy women. Basal apo B-48 concentrations
were significantly associated with those of triglycerides (r=0.63, P<0.001) and
cholesterol (r=0.58, P<0.001) in the TGRL fraction.
Table 3. Serum lipids in women with and without CAD
                                                                                                                                                      
   Variable                  Studies I & II                       Study III                         Study IV       
                                        Cases       Controls        Cases        Controls        Cases          Controls
                                      (n=25)         (n=30)      (n=48)          (n=61)        (n=29)          (n=20)    
Total CH, mM             6.08±0.21   5.72±0.16   5.94±0.14   5.71±0.12    6.13±0.17   5.85±0.29 
LDL CH, mM             3.75±0.17*  3.24±0.13  3.99±0.12*  3.66±0.12    4.23±0.16   3.82±0.25
HDL CH, mM             1.29±0.05    1.31±0.05  1.31±0.03†  1.50±0.05   1.29±0.09* 1.52±0.07
Non-HDL CH, mM     4.78±0.19    4.40±0.15  4.66±0.14†   4.21±0.13  4.85±0.17* 4.33±0.32
LDL/HDL CH             3.00±0.17*  2.55±0.12  3.19±0.14‡   2.61±0.13  3.38±0.17† 2.67±0.27
Triglycerides, mM       1.26±0.09    1.27±0.08  1.39±0.09     1.21±0.09  1.35±0.09* 1.11±0.19
Apo B-100, mg/dl       115.3±4.6    103.9±4.6         ND                 ND           ND             ND
TGRL apo B-48, mg/l  3.10±0.39†  1.67±0.22        ND                 ND           ND             ND
                                                                                                                                                      
* P<0.05, † P<0.01, ‡ P<0.001, Cases vs Controls; CH=cholesterol; ND = not determined.
     The cases were more likely to have a family history of CAD, a higher frequency o f
smoking, and hypertension. For instance, in the whole study population, 81% of the CAD
patients and 33% of the healthy women had a family history of CAD (P<0.001). Of the
cases, 54%, and 29% of the healthy women smoked cigarettes (P<0.05), and  46% of the
cases and 24% of the controls suffered from hypertension (P<0.05). The coronary
patients’ levels of  hemoglobin and leukocytes were higher than those of the healthy
women (Table 1 in Study III). Blood hemoglobin levels were significantly higher in the
smokers than in the nonsmokers in CAD (146.2 ± 1.9 vs 140.9 ± 1.9 g/l, P<0.05) and
control (142.3 ± 2.3 vs 136.5 ± 1.4 g/l, P<0.05) groups, and these levels were positively
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associated with serum cholesterol levels (Fig.5). Serum insulin and blood glucose levels
were similar between the groups, but serum GHbA1c% was higher in the cases than in
controls. GHbA1c % was positively associated with levels of LDL cholesterol and serum
triglycerides, and inversely with HDL cholesterol and serum SHBG levels. Due to their
high prevalence of hypertension, cases were mostly on beta- and calcium-blocking
agents. HRT was used by 37% of the cases and 46% of the controls (P=NS). In no study
did HRT or beta- and calcium-blocking agents show any effect on baseline variables, by
subgroup analyses. 
    The association of the above risk factors with CAD was tested by logistic regression
analyses for the whole study population (Table 4). In univariate analysis, the presence of
CAD was positively associated with LDL cholesterol, family history of CAD, smoking,
hypertension, blood hemoglobin, and GHbA1c %, and inversely with HDL cholesterol
level. In the multivariate model, including BMI, family history of CAD, smoking,
hypertension, LDL and HDL cholesterol levels, serum triglycerides, GHbA1c% and
HRT, and beta-blocking therapy, only GHbA1c % and family history of CAD were
significantly associated with CAD. Adding SHBG, insulin, or blood glucose to the model
or substituting serum total cholesterol for LDL cholesterol did not substantially alter the
independent association of CAD with GHbA1c% or with family history of CAD. LDL
cholesterol became significantly associated with CAD after addition of squalene to the
multivariate model (Table 4 in Study III).
Table 4.  Associations between risk factors and CAD in postmenopausal women
                                                                                                                                           
     Variable                                  Univariate analysis   Multivariate analysis
                                                                                                                                           
BMI                                       -0.36 (-0.75)                         -0.08 (-1.08)
Family history of CAD                      2.18 (4.75) ‡                         1.61 (2.44) *
Smoking                                             0.91 (2.25) *                         0.89 (1.39)
Hypertension                                      0.86 (2.07) *                        -0.02 (-0.03)
HRT                                                  -0.16 (-1.10)                           0.21 (0.88)
-blocker users                                  3.10 (5.81) ‡                          2.74 (4.14) ‡
LDL cholesterol                                 0.45 (2.05) *                          0.35 (1.03)
HDL cholesterol                               -2.03 (-2.94) †                       - 0.64 (-0.58)
Serum triglycerides                            0.39 (1.33)                            -0.21 (-0.41)
Hemoglobin                                       0.06 (2.79) †                          0.01 (0.18)
GHbA1c                                            1.90 (3.41) ‡                          1.95 (2.21) *      
                                                                                                                                           
Values are coefficient (/SE). * P<0.05, † P<0.01 and ‡ P<0.001.
y = 0.02x + 2.43
r = 0.25, p=0.01
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            Fig.5. Blood hemoglobin and serum cholesterol in all subjects
5.2.  Serum squalene    
5.2.1.  Squalene and lipoprotein lipids (Study I)
    This study focused on fasting squalene concentration and its lipoprotein distribution
in CAD and control women. Serum squalene concentration was significantly higher in
CAD than in control women (Table 1 in Study I). In chylomicrons, VLDL, and d>1.006
g/ml lipoproteins, squalene concentrations ranged from 2.0 to 11.8, 4.1 to 40.0, and 27.6
to 104.6 µg/dl, respectively, and were significantly higher in all lipoprotein fractions of
CAD than of control women (Fig.6). The percentage distribution of squalene was similar
in the cases and controls: 4.7 vs 5.4 % in chylomicrons, 16.4 vs 15.9 % in VLDL, and
78.9 vs 78.6% in d>1.006 g/ml lipoproteins. The squalene ratios to cholesterol or
triglycerides were also elevated in serum and in all lipoproteins except in the
chylomicron fraction of the CAD patients (Table 1 in Study I). In decreasing order for
the squalene-to-cholesterol ratio were: chylomicrons, VLDL, and d>1.006 g/ml
lipoproteins, and for the squalene-to-triglyceride ratio were: chylomicrons, d>1.006 g/ml
lipoproteins, and VLDL.The lipoprotein distribution of squalene was similar among
hormone users and nonusers in both groups. 
      
F i g . 6 .
Squalene distribution in serum lipoproteins of women with and without CAD
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      Squalene and cholesterol concentrations were significantly correlated with each other
in serum (r=0.52, P<0.001), VLDL (r=0.85, P<0.001), and in d>1.006 g/ml lipoproteins
(r=0.55, P<0.001), but not in chylomicrons, suggesting that in the fasting state, intestinal
squalene accumulation in the chylomicrons was unrelated to that of cholesterol. In
VLDL, the regression equations for cholesterol versus squalene differed between CAD
and control women (Fig.1 in Study I). Thus, if VLDL was separated into two groups
based on its median, the squalene levels were significantly higher in the CAD than in
control women for the lower half of VLDL cholesterol (0.35 mmol/l) and were
comparable with each other for the upper half of VLDL cholesterol (>0.35 mmol/l). In
other words, in the CAD women, the fasting sterol mixture in VLDL was rich in
squalene at the low VLDL cholesterol level, but not at the high VLDL cholesterol level.
This suggests that in CAD women, serum squalene levels were higher when hepatic
VLDL production was lower, probably due to low cholesterol synthesis. The squalene
levels were associated with those of triglycerides exclusively in VLDL (r=0.84,
P<0.001). Furthermore, a significant positive association appeared between fasting
squalene and apo B-48 levels in TGRL (r=0.71, P<0.001).
5.2.2.  Postprandial squalene and other lipids (Study II) 
   In order to evaluate the dietary squalene contribution to serum squalene concentrations,
postprandial squalene metabolism for a 24-h period was assessed following
administration of a fat meal containing squalene and vitamin A. Postprandial levels of
squalene, retinyl palmitate, and apo B-48 reflect the magnitude of postprandial
lipoproteinemia.
Postprandial squalene 
  Postprandially, a significant elevation in squalene concentration was seen in
chylomicrons and in VLDL from 3 hours onwards in both cases and controls. Squalene
concentrations peaked at 7.17 ± 0.42 h and 8.12 ± 0.49 h in chylomicrons and VLDL,
respectively, in the CAD patients, whereas in the healthy controls, peak times were
significantly delayed in VLDL (8.63 ± 0.46 h) compared with times for chylomicrons
(6.97 ± 0.36 h, P<0.01) (Fig.7). In chylomicrons, ratios of squalene to triglycerides were
clearly higher than in VLDL throughout the 24-h period in both groups (Table 3 in Study
II). Postprandial squalene concentrations peaked at about 9 hours in d>1.006
lipoproteins, and subsequently returned to basal values at 24 hours (Fig.1 in Study II).
      ANOVA for repeated measures revealed that the CAD group had significantly higher
postprandial squalene concentrations in TGRL, chylomicrons, and VLDL than did the
control group, and that the 24-h curves (both absolute and incremental curves) were
situated higher for case than control groups (Figs.1 & 2 in Study II, Fig.8). Compared
with the control values, the cases clearly had higher AUICs and PIC values in TGRL,
chylomicrons, and VLDL (Table 2 in Study II). TGRL AUICs were significantly
56
7
8
9
10
11
Cases Controls
chylomicrons
VLDL
d>1.006 g/ml
Sq
ua
le
ne
 p
ea
k 
tim
e,
 h
ou
r
*
* P<0.05, VLDL vs chylomicrons
¤
¤ P<0.05, d>1.006 lipoproteins vs VLDL
0
100
200
300
400
500
600
Time, hour
µg
/d
l *
Cases
Controls
TGRL-squalene
P=0.007 by ANOVA, 
Cases vs Controls
|
3 6 9 12 24
-2
-1
0
1
2
3
4
m
g/
l *
Cases
Controls
Time, hour
TGRL-apo B-48
|
4 6 9 24
P<0.001 by ANOVA, 
Cases vs Controls
43
correlated with basal levels of TGRL squalene and LDL cholesterol. However, adjusted
AUICs for baseline TGRL squalene and LDL cholesterol were still significantly higher
in the CAD women than in controls (Table 5). The higher the baseline serum squalene
levels, the higher were the squalene AUICs in chylomicrons (Fig.9). Thus, baseline
squalene levels predicted postprandial squalene responses for both groups. 
   Fig.7. Peak times of squalene in chylomicrons, VLDL, and d>1.006 lipoproteins    
               of CAD women and controls  
    Fig.8.  Postprandial 24-h curves for TGRL-squalene and apo B-48 of CAD women
                and controls. * postprandial
concentration minus basal concentration 
    
Table 5. Adjusted TGRL squalene AUICs (mg/dl*h) and TGRL apo B-48 AUICs      
           (mg/l*h) for women with and without CAD   
                                                                                                                                           
         Variable                                                                    Cases        Controls     P value
Adjusted squalene AUICs for basal TGRL squalene      5.78 ± 0.48    4.28 ± 0.43   <0.05
Adjusted squalene AUICs for basal LDL cholesterol     6.02 ± 0.54    4.11 ± 0.47   <0.01
Adjusted apo B-48 AUICs for basal TGRL apo B-48   19.9 ± 2.3      11.5 ± 1.9      0.01
Adjusted apo B-48 AUICs for basal LDL cholesterol   19.2 ± 2.2      11.7 ± 1.9    <0.05
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Fig. 9. Basal serum squalene and chylomicron squalene AUICs in cases and controls
Postprandial triglycerides and cholesterol 
    After the fat meal, triglyceride and cholesterol levels were significantly raised in
chylomicrons and VLDL in both groups (Fig.2 in Study II, and Fig.10). These
concentrations peaked similarly in the cases and controls at about 4 hours and then
returned to basal levels after 6 hours in the VLDL fraction. The CAD and control women
had comparable postprandial concentrations, 9-h AUICs and PIC of triglycerides, and
cholesterol in chylomicrons, VLDL, and d>1.006 g/ml lipoproteins (Figs.1 & 2 and
Table 2 in Study II). The AUICs of TGRL triglycerides could be predicted by fasting
serum triglycerides, TGRL squalene, and VLDL cholesterol (Table 4 in Study II), and
were significantly associated with TGRL squalene AUICs (r=0.72, P<0.001).    
     
          
 
          
  Time, hour
Fig.10. Postprandial cholesterol
levels in chylomicrons, VLDL,
and  d>1.006 lipoproteins of CAD
women and controls
                           Time, hour
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Postprandial TGRL apolipoprotein B-48
     Postprandial apo B-48 levels were elevated like to those of cholesterol and
triglycerides. But in contrast to the latter postprandial responses, the postprandial TGRL
apo B-48 concentrations, especially at 6 hours, and the curve for the CAD patients
differed significantly from those of controls (Fig.1 in Study II, Fig.8). The CAD patients
also had higher 9 h-AUICs, PIC, and peak time (4.87 ± 0.21 vs 4.33 ± 0.14 h, P<0.05)
compared with those of controls (Table 2 in Study II). The AUICs were significantly
associated with basal TGRL apo B-48, LDL cholesterol, serum triglyceride, and VLDL
cholesterol levels in all subjects (Table 4 in Study II). However, adjusted AUICs for
basal TGRL apo B-48 and for LDL cholesterol were still significantly higher in cases
than in controls (Table 5). Significant associations existed between the AUICs of apo B-
48 and of triglycerides (r=0.61, P<0.001) and squalene (r=0.55, P<0.001) in TGRL.
Postprandial retinyl palmitate 
      Postprandial retinyl palmitate, like squalene, peaked at about 6 hours in chylomicrons
and VLDL of the cases, but in the controls, postprandial concentrations peaked
significantly earlier in chylomicrons than in VLDL (6.10 ± 0.28 vs 8.06 ± 0.50 h).The
24-h levels returned to basal values for chylomicrons and for VLDL. In d>1.006 g/ml
lipoproteins, the 24-h levels were still significantly elevated in both CAD (+24.7 ± 2.8
µg/l) and control (+30.4 ± 2.1 µg/l) groups, despite normalization of the respective
squalene values. The CAD women and healthy controls had comparable postprandial
retinyl palmitate concentrations in all lipoproteins, but the AUICs and PIC of VLDL
were significantly higher in the CAD patients  (Figs.1 & 2 and Table 2 in Study II).
Postprandial TGRL AUICs were significantly associated with TGRL apo B-48 AUICs
(r=0.53, P<0.001) and squalene AUICs (r=0.82, P<0.001). Thus, the present study
confirms an earlier study’s findings (Gylling and Miettinen 1994) that dietary squalene
can serve as a postprandial lipoprotein marker.  
5.2.3.  Serum squalene and CAD (Study III)
      This study examined serum squalene concentrations in the whole study population
and revealed their association with the presence of CAD. Serum squalene levels and the
squalene-to-cholesterol ratio were normally distributed, ranging from 30.0 to 132.0 µg/dl
and 11.3 to 62.2 10  x mmol/mol of cholesterol, respectively (Fig.11), and were higher2
in the cases than in the controls (91.3 ± 2.4 vs 60.8 ± 2.1 µg/dl, P<0.001 and 42.1 ± 1.2
vs 28.2 ± 0.9 10  x mmol/mol of cholesterol, P<0.001, respectively). These ratios were2
also significantly higher for the cases in each cholesterol quartile (Fig.12).
      The ratio of squalene to cholesterol was inversely associated with serum total
cholesterol levels in the coronary patients but less consistently in the controls (Fig.1 in
Study III), even though the squalene values falling below the median showed a
significant correlation (r=-0.30, P<0.05). Squalene ratios were lower for controls than for
cases, especially at low and high cholesterol levels, and were significantly and positively
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cases, especially at low and high cholesterol levels, and were significantly and positively
associated with GHbA1c % and family history of CAD (P<0.001), and negatively with
HDL cholesterol level (Table 3 in Study III).
a:#50
b:>50#60
c:>60#70
d:>70#80
e:>80#90
f:>90#100
g:>100#110
h:>110
                        
                                            Squalene concentration, µg/dl
i:#20 
j:>20#25
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                         Squalene/cholesterol ratio, 100x (mmol/mol of cholesterol) 
           Fig. 11. Distribution of serum squalene in women with and without CAD
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   Fig. 12. Serum squalene in women defined by cholesterol quartiles
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     In logistic regression analyses, after adjustment for age, BMI, family history of CAD,
smoking, hypertension, LDL and HDL cholesterol levels, serum triglycerides, and
GHbA1c%, serum squalene was significantly associated with the presence of CAD
(Table 4 in Study III). Substituting total for LDL cholesterol or adding other variables
did not alter the magnitude of this association. Furthermore, ROC curve analyses
indicated that squalene ratios correctly predicted cases and controls at a probability of
88.5% (Fig.2 in Study III). The respective values for LDL cholesterol, serum
triglycerides, the ratio of LDL to HDL cholesterol, and non-HDL cholesterol were
65.1%, 61.7%, 69.1%, and 61.8%, respectively.
 5.3.  Serum noncholesterol sterols and CAD (Study III)
         In addition to serum squalene, noncholesterol sterols were also measured in the
serum of the whole study population. Serum levels of cholestenol and cholestanol were
similar, but those of desmosterol, campesterol, and sitosterol were significantly higher
and those of lathosterol were lower in the cases than in the controls (Table 2 in Study
III). The respective ratios to cholesterol also differed for the serum of CAD women
(Fig.13). 
       Fig. 13. Serum noncholesterol sterols in women with and without CAD     
      None of the ratios of noncholesterol sterols to cholesterol were associated with serum
total cholesterol level. A positive association was found between desmosterol and
squalene ratios for all subjects (r=0.21, P<0.05). The ratios of desmosterol and
lathosterol were related inversely to those of plant sterols (P<0.01) and HDL cholesterol
and SHBG, and positively to BMI, serum triglyceride, and insulin levels (Table 3 in
Study III). The latter variables and blood glucose levels were inversely associated with
ratios of plant sterols and cholestanol. Significant relationships existed between family
history of CAD and serum desmosterol and sitosterol. 
    In univariate logistic regression analysis, the presence of CAD was associated
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positively with serum desmosterol, campesterol, and sitosterol and inversely with
lathosterol (Table 4 in Study III). Adjustment for age, BMI, family history of CAD,
smoking, hypertension, LDL and HDL cholesterol levels, serum triglycerides, and
GHbA1c% eliminated the association of CAD with desmosterol, attenuated its
association with lathosterol, and left unaffected its association with plant sterols. Adding
SHBG, insulin or blood glucose to the models separately or substituting serum total for
LDL cholesterol in each model did not essentially alter the results.
 5.4.  Squalene, cholesterol metabolism, and CAD (Study IV)
      In order to evaluate fecal squalene output, and to substantiate the altered cholesterol
metabolism in CAD women versus control women, and to investigate the associations of
serum squalene, sterols, and other lipids with baseline cholesterol metabolism, the sterol
balance and cholesterol absorption were determined for 29 cases and 20 controls. In these
two groups, dietary intakes of cholesterol and fat, and energy percentage of SAFA,
MUFA, and PUFA were similar (Table 1 in Study IV). Alanine aminotransferase activity
was comparable among cases and controls (29.2 ± 3.1 vs 24.6 ± 2.7 U/l, P= NS).
  The CAD women showed significantly lower fecal excretion of squalene,
dihydrolanosterol, endogenous neutral steroids and total steroids than did controls
(Fig.14). Fecal campesterol and sitosterol were comparable in both groups, suggesting
that dietary intake of plant sterols did not differ between cases and controls. The CAD
women had also lower levels of cholesterol synthesis and turnover and biliary and
intestinal cholesterol flux. Subsequently, the absorbed mass of total and biliary
cholesterol was lower in the cases than in the controls despite their similar cholesterol
absorption efficiency (Table 2 in Study IV).                                                                  
           Fig. 14.  Fecal squalene and steroids in women with and without CAD 
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family history of CAD, smoking, LDL (or total cholesterol) and HDL cholesterol, and
serum triglyceride levels showed that the absorbed mass of biliary cholesterol, fecal total
steroid output, cholesterol synthesis and turnover, and biliary cholesterol secretion, and
intestinal cholesterol pool were inversely associated with the presence of CAD (Table 3
in Study IV).     
     In all subjects, an inverse relationship existed between the synthesis and absorption
efficiency of cholesterol (Fig.15). Serum lathosterol values, but not the values for
squalene and for desmosterol, were significantly correlated with cholesterol synthesis
(r=0.53, P<0.001). Serum squalene values were negatively correlated with fecal squalene
excretion and biliary cholesterol flux in subjects with below-median values for
cholesterol synthesis, biliary secretion of cholesterol, and fecal squalene output (Table 4
and Fig.1 in Study IV). Fecal squalene excretion was significantly positively correlated
with cholesterol synthesis and biliary cholesterol flux, especially in subjects above the
median levels for cholesterol synthesis, biliary secretion of cholesterol, and fecal
squalene. Cholesterol absorption efficiency was positively correlated with serum
campesterol (r=0.36, P=0.01), sitosterol (r=0.32, P<0.05), and HDL cholesterol levels
and inversely with serum triglyceride level, which in turn was positively related to
cholesterol synthesis (Table 6). The latter one was significantly related to BMI (r=0.42,
P<0.01). Blood glucose levels were correlated with cholesterol synthesis (r=0.42,
P<0.05) and cholesterol absorption efficiency (r=-0.41, P<0.05) in the cases, but less
consistently in the controls. In the cases, total and LDL cholesterol level were
significantly related to fecal bile acids (Fig.2 in Study IV, Table 6). In stepwise
regression analysis, with cholesterol absorption efficiency and fecal bile acids as
independent variables, and LDL or HDL cholesterol as dependent variables, 20% and
24% of the respective variabilities of LDL and HDL cholesterol concentrations in the
study population could be explained by fecal bile acids.
                                    
           
            Fig. 15.
Cholesterol absorption efficiency and synthesis 
                          in women with and without CAD
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Table 6. Cholesterol metabolism in CAD women (n=29) and controls (n=20) related to
               serum lipids
                                                                                                                                           
                                                                     Cholesterol                                       Serum
Variable                                   Total                     LDL                   HDL              triglycerides
                                           Cases  Controls   Cases  Controls   Cases  Controls  Cases Controls
Cholesterol absorption, %       0.18    0.18        0.25     0.18       0.43*   0.49*   -0.51†    -0.44   
Absorbed total cholesterol       0.35    0.06        0.34     0.09       0.42*    0.16    -0.12      -0.04
Intestinal cholesterol flux        0.32   -0.04        0.26     0.00       0.08    -0.15      0.34       0.27
Fecal bile acids                      -0.47*  -0.21      -0.57†   -0.17       0.20    0.26       0.01      0.00
Fecal neutral steroids              0.16    -0.10       0.07     -0.08      -0.16   -0.28      0.54†     0.45
Fecal total steroids                 -0.17   -0.24      -0.29     -0.22       0.03     -0.20     0.36       0.35
Cholesterol synthesis             -0.01   -0.23      -0.11    -0.22       -0.05    -0.24      0.40*     0.46
                                                                                                                                                      
 Values are correlation coefficients. * P<0.05,  † P<0.01
5.5.  Treatment with sitostanol ester and simvastatin (Study V) 
     The study focused on the effects of sitostanol ester margarine alone on cholesterol
malabsorption, and on subsequent reduction in serum lipid levels and enhancement of
cholesterol synthesis in CAD women. Another approach was to combine the cholesterol
malabsorption caused by stanol esters with the inhibition of cholesterol synthesis caused
by statins. Of major interest was discovering any effects of changes in cholesterol
metabolism on serum squalene. Replacement of control rapeseed oil margarine for home
dietary fat tended to reduce the intake of SAFA, increase that of MUFA, PUFA, and the
PUFA/SAFA ratio, and reduced significantly that of cholesterol (Table 1 in Study V).
Serum and lipoprotein lipids
       Rapeseed oil margarine reduced cholesterol levels in serum, VLDL, and LDL, and
triglycerides of HDL (Table 2 in Study V). Of the patients, 32% exhibited a reduction in
serum cholesterol levels after their consumption of this margarine (Fig.1 in Study V).
Sitostanol ester margarine reduced serum total, IDL, and LDL cholesterol levels by 13%,
25%, and 20%, respectively, from home diet values, and by 8%, 14%, and 15%,
respectively, from control margarine values (Fig.16). In all patients, serum cholesterol
concentrations fell (Fig.1 in Study V). Sitostanol ester margarine also significantly
reduced triglyceride concentrations of LDL and HDL below home diet values (Fig.16).
Adding sitostanol ester margarine to simvastatin-treated CAD women further reduced
total and LDL cholesterol by 11% and 16%, respectively (Table 5 in Study V), such that
the corresponding overall reductions were 32% and 46%. On simvastatin, 30% of
patients had a LDL cholesterol level <2.6 mmol/l, but after addition of sitostanol ester
margarine, 80% of  patients had reached that target level. 
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Fig. 16. Effects of sitostanol ester on serum and lipoprotein lipids in women with CAD
  
Cholesterol metabolism
     Sitostanol ester margarine decreased cholesterol absorption efficiency and absorbed
mass of dietary and biliary cholesterol by 45%, 50%, and  44%, respectively, and
increased fecal total steroids by 28% (Table 4 in Study V). The increased output of fecal
neutral steroids of cholesterol origin (+45%) was contributed by contents both of dietary
and of biliary origin, resulting in enhanced synthesis (+39%) and turnover (+17%) of
cholesterol. The increase in cholesterol synthesis was inversely associated with baseline
cholesterol synthesis. The higher the cholesterol absorption efficiency in the home die t
period, the higher was its reduction by sitostanol ester margarine, and all changes in
cholesterol absorption efficiency were significantly associated with changes in LDL
cholesterol concentrations (r=0.44, P<0.05).
Serum squalene and noncholesterol sterols
     Serum squalene concentration and its ratio to cholesterol were all significantly
reduced by use of rapeseed oil margarine (Table 7). None of the noncholesterol sterols
were affected, but campesterol ratios were enhanced (Table 3 in Study V). Sitostanol
ester margarine significantly reduced squalene concentrations from their home diet
values, but the ratios to cholesterol remained unchanged, and the change caused by
sitostanol ester was insignificant. The ratios of campesterol, sitosterol, and cholestanol
were reduced by about 33%, 19%, and 12%, respectively, and the ratios of desmosterol
and lathosterol were raised by 12% for both (Table 3 in Study V). Additional analysis
showed that fecal output of squalene was significantly enhanced by use of rapeseed oil
margarine; however, addition of  the stanol ester had no effect on fecal squalene, despite
a clear increase in fecal elimination and synthesis of cholesterol, as shown by sterol
balance data and precursor sterols in serum. Reduction in cholesterol synthesis caused by
simvastatin had no effect on serum squalene levels ( -8.50 ± 7.41 µg/dl, P=NS), even
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though other cholesterol precursors were reduced. Neither a combined administration of
simvastatin and sitostanol ester affected serum squalene levels ( -7.16 ± 8.10 µg/dl,
P=NS).
Table 7.  Serum and fecal squalene during dietary intervention with rapeseed oil      
               margarine with and without sitostanol ester in women with CAD (n=22)   
                                                                                                                                           
                                                          Serum squalene                            Fecal squalene
                                                 µg/dl         100 x (mmol/mol                     µg/kg/day
                                                                          of cholesterol)                                          
Home diet (HD)              90.9 ± 4.0         39.9 ± 2.0                    84.4 ± 11.0   
Rapeseed oil margarine (RM)     80.4 ± 4.7        36.3 ± 1.5                      109.4 ± 9.2   a a a
Sitostanol ester margarine (SM) 75.8 ± 4.5        37.8 ± 1.9                  108.4 ± 10.6b
% change
       (RM-HD) / HD             -11.1 ± 4.7 *    -7.56 ± 4.45                   28.1 ± 9.9 *
       (SM-RM) / RM             -3.24 ± 3.45      6.25 ± 3.87                  -2.77 ± 5.1
       (SM-HD) / HD             -15.3 ± 4.3     -2.87 ± 4.80                      25.8 ± 10.2*
                                                                                                                                           
  
 P<0.05,  P<0.01, compared with home diet values; * P<0.05,  P<0.01a b
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6.  DISCUSSION
6.1.  Study population
    This is a case-control study. CAD was verified by coronary angiography with an
occlusion of at least 50% in major coronary arteries. The control women had no clinical
manifestation of CAD or ST-T changes in their resting ECG, so that stress ECG or
coronary angiography was not considered necessary. Both groups of  women were
postmenopausal, and about 37% of the cases and 45% of the controls used HRT, which
are similar to frequencies reported in the whole population (National Pensions Institute,
Finland, 1997). In order to learn the effects of HRT, subgroup analyses were performed
in each study. There was only a trend toward lower serum and LDL cholesterol levels,
and the significant expected elevation of SHBG in the women on HRT, but no other
differences were observed between the groups. In consideration of other potential
confounding factors regarding cholesterol and postprandial lipoprotein metabolism, both
groups were well matched for BMI, and  apo E distribution was similar in the cases and
controls. Most of the CAD women were hypertensive; however, their blood pressure was
similar to that of controls due to -blocker medication.  -blockers increase serum
triglyceride level, decrease HDL cholesterol, and have nonsignificant effects on serum
and LDL cholesterol concentrations (Cruickshank 1990, Kasiske et al 1995). In the
present studies, however, no differences in serum squalene and sterols existed between
the  -blocker users and non-users. 
6.2.  Baseline characteristics
       According to the NCEP guidelines ((Expert Panel on Detection, Evaluation, and
Treatment of High Blood Cholesterol in Adults 1993), serum cholesterol levels of these
cases were very high for CAD patients. However, the majority of the cases were not
being treated for hypercholesterolemia. Even though serum total cholesterol was
comparable, the cases had elevated LDL cholesterol and lower HDL cholesterol than had
the controls. Thus, in the cases, ratios of LDL to HDL cholesterol and total to HDL
cholesterol were significantly elevated. Compared to serum total cholesterol level, the
ratio of total to HDL cholesterol has been documented to be a stronger risk factor for
CAD, especially in women (Simons 1986, Romm et al 1991). 
       The family history of CAD was more common in the cases than in the controls,  and
it was independently associated with the presence of CAD, in concordance with earlier
studies (Myers et al 1990, Pohjola-Sintonen et al 1998). The cases smoked more
frequently than did the controls. In agreement with an earlier study, blood hemoglobin
concentrations were higher in the cases than in the controls (Böttiger and Carlson 1973).
On the other hand, the smokers had higher blood hemoglobin levels than had the non-
smokers. This suggests that high hemoglobin levels in the cases were due to the high
frequency of smokers. Elevated hemoglobin level has indeed been observed among
female smokers (Ernst et al 1988). Although high hemoglobin level was associated with
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high serum cholesterol level in this population, both were not independently associated
with the presence of CAD.
Glycosylated hemoglobin A1c and CAD
     The occurrence of CAD  is related to increasing fasting glucose in the normal range,
especially in women (Simons et al 2000). In the present cases and controls, blood glucose
levels, as well as GHbA1c% fell in the normal range, but in contrast to blood glucose
levels, GHbA1c% was independently associated with the presence of CAD in these
postmenopausal women, in agreement with a previous finding (Laakso 1996). Positive
associations of GHbA1c% with LDL cholesterol and serum triglycerides, and its negative
association with HDL cholesterol level may in part explain its relation to CAD. In
addition, its associations with squalene and desmosterol indicate that high cholesterol
synthesis through the unsaturated side-chain pathway characterizes women with high-
normal blood GHbA1c%. 
        Blood glucose level was inversely associated with the ratios of plant sterol and
cholestanol, suggesting that the higher the blood glucose level, the lower was the
cholesterol absorption efficiency and the higher was the cholesterol synthesis rate,
findings observed also in nondiabetic men (Strandberg et al 1996). The sterol balance
data indicated that blood glucose levels, cholesterol synthesis, and cholesterol absorption
efficiency were interrelated, especially in the cases. Cholesterol absorption efficiency and
synthesis are indeed lower and higher, respectively in diabetic patients than in control s
(Sutherland et al 1992, Gylling and Miettinen 1997). In agreement with Sutherland et al
(1992), high serum insulin was significantly related to high cholesterol precursor ratios. 
In addition, the latter were inversely correlated with serum SHBG levels, suggesting a
relationship between cholesterol synthesis and insulin resistance syndrome. Insulin
suppresses hepatic secretion of SHBG (Plymate et al 1988) and increases HMG CoA
reductase activity, hence has the effect of increasing hepatic cholesterol synthesis
(Lakshmanan et al 1973). 
 6.3.  Serum squalene and CAD  
    The present study revealed for the first time that serum squalene levels are higher in
postmenopausal women with than without CAD, suggesting that such levels may relate
to the development of CAD. Serum squalene was strongly associated with the presence
of CAD even after adjustment for conventional risk factors such as serum or LDL
cholesterol, HDL cholesterol, serum triglycerides and smoking. Only a few studies have
focused on serum squalene concentration in those pathologic state in which cholesterol
metabolism is altered. Abnormal serum squalene levels have been reported in patients
with influenza (Gallin et al 1970) and hepatobiliary diseases. Compared with normal
subjects, the serum levels were higher in hepatocellular carcinoma (Hirayama et al 1979),
lower in intra- and extrahepatic cholestasis (Yamanishi et al 1978, Hirayama et al 1979),
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and did not change in hepatitis and liver cirrhosis (Yamanishi et al 1978, Nikkilä et al
1992). Compared with levels in controls, serum squalene levels were higher,
corresponding to higher cholesterol synthesis, in diabetic patients (Gylling and Miettinen
1997). 
Diet and serum squalene
      Serum squalene is derived from intestinal or liver cells either from dietary intake or
from de novo synthesis. The richest dietary source of squalene is olive oil. Dietary
squalene with biliary squalene forms a small but significant amount of intestinal
squalene. In the intestine, squalene is absorbed similarly with cholesterol and secreted
into the circulation in chylomicrons. But unlike cholesterol, most of the intestinal
squalene pool (about 60-85%) is absorbed (Strandberg et al 1990, Miettinen and
Vanhanen 1994). Squalene feeding in high amounts elevates serum squalene
concentrations (Liu et al 1976, Tilvis and Miettinen 1983a, Strandberg et al 1990,
Miettinen and Vanhanen 1994). Following the present single dose of 500 mg squalene in
the fat meal, the postprandial squalene concentrations in serum lipoproteins rose within
6 to 9 hrs and returned to basal levels within 24 hrs, in concordance with earlier findings
(Gylling and Miettinen 1994). However, the same amount of squalene fed for 6 weeks
increased only slightly its fasting serum concentrations (Miettinen and Vanhanen 1994).
In the present study, the dietary fat and MUFA intakes were similar in the two groups,
and virtually no olive oil was being used. Rapeseed oil, which is very low in squalene
(Miettinen and Vanhanen 1994), was the major source of MUFAs. Dietary intake of
squalene was calculated to be very low, <20 mg/day and was similar in both groups, such
that dietary squalene was not a confounding factor in the fasting squalene concentrations.
Thus, the high serum squalene levels in the coronary patients were most likely of
endogenous origin. 
High serum squalene
      What could be the mechanism of high serum squalene concentrations in these CAD
women?  The slightly higher fasting squalene level in chylomicrons of the CAD than of
the control women suggests its intestinal origin and mostly its being synthezised by
mucosal cells or biliary origin, whereas elevated squalene in the VLDL and VLDL
bottom may point mainly to its hepatic origin. Effective absorption of squalene from
reduced intestinal cholesterol pool in the CAD women may have contributed to increased
chylomicron squalene and subsequently that in the VLDL and VLDL bottom. High
squalene and cholesterol concentrations in the VLDL bottom may be due either to
enhanced conversion of VLDL to LDL  or to decreased clearance of d>1.006
lipoproteins. The high ratio of squalene to cholesterol implies that hepatic sterol
metabolism had been altered in the CAD women. Studies of the daily diurnal rhythm of
cholesterol precursors have shown that squalene and methyl sterols are highest from
56
midnight to the early morning hours, indicating markedly enhanced de novo cholesterol
synthesis up to 4 am (Miettinen 1982a). There may be a delay in downregulation of this
normal diurnal rhythm in CAD women, resulting in formation of squalene-rich VLDL
particles in the low range of VLDL cholesterol (Fig.1 in Study I) and triglyceride
concentrations, and in higher fasting squalene in circulating lipoproteins of the CAD
women.
       A high amount of squalene is found in skin and adipose tissues (Liu et al 1976), and
these tissues are capable also of synthesizing squalene and cholesterol (Miettinen and
Tilvis 1981). Thus, part of the serum squalene can also originate extrahepatically.
However, one in-vitro study demonstrated that in contrast to cholesterol, squalene is
rarely released into plasma lipoproteins from the adipocytes (Tilvis et al 1978). In fact,
serum squalene level was not correlated with adipose tissue squalene content (Miettinen
and Tilvis 1981). Part of the hepatic squalene is secreted into the bile, and biliary leve l
of squalene was significantly associated with that of cholesterol (Nosaka et al 1985).
Study IV showed that fecal squalene output was lower in the CAD women than in
control women, and was associated with cholesterol synthesis and biliary cholesterol
secretion, suggesting that biliary secretion of squalene was also low in the CAD women.
Furthermore, serum squalene levels were inversely associated with fecal squalene
excretion in subjects with low biliary cholesterol output. This implies that high serum
squalene levels in the cases are caused in part by reduced biliary lipid secretion. 
      
Squalene and atherosclerosis
      A dynamic interaction among circulatory lipoproteins and lipid metabolism of the
arterial wall leads to atherosclerosis (Getz et al 1969). Cholesterol of the arterial wall is
mostly derived from plasma lipoproteins (Chobanian and Hollander 1962, Smith  and
Slater 1972). On the other hand, arterial tissues are capable of synthesizing cholesterol
(Siperstein et al 1951, Chobanian 1968, Daly 1971). However, the fatty acid composition
of normal intima and of plaques differ (Böttcher et al 1960, Chobanian and Manzur
1972). Oleic acid content was higher, but palmitic, stearic, and linoleic acids were lower
in the cholesteryl ester fraction of the fatty streaks compared to that of the normal intima,
reflecting intracellular cholesteryl esters present in foam cells in the fatty streaks. In
addition to cholesterol, squalene has also been identified in human arterial intima (Liu
et al 1976) and atherosclerotic plaques (Brooks et al 1966, Lewis 1975). Squalene can be
synthesized in human arterial segments (Chobanian 1968, St.Clair et al 1968) and
atherosclerotic lesions (Chobanian 1968). After C-labeled acetate administration, a14
substantial amount of radioactivity (5.7- 28.7% of cholesterol) was found in the squalene
fraction (Chobanian 1968), suggesting that in atherosclerotic arterial tissue, squalene is
a major intermediate of cholesterol biosynthesis. Eventhough the cholesterol synthesis
rate is slower in arterial tissue than in the liver (Daly 1971), accumulation of squalene
may occur in the arterial wall if post-squalene cholesterol biosynthesis is interrupted. The
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squalene content detected in arterial intima is approximately 0.3% of the cholesterol
content (Liu et al 1976). In our CAD women, serum concentration of squalene is
approximately 0.04% of that of cholesterol. This suggests that squalene:cholesterol
proportion is higher in arterial tissues than in the circulation, probably due either to
enhanced de novo squalene synthesis or to retarded cyclization of squalene to cholesterol
in the arterial tissue (Fig.17). Similarly to cholesterol, deposition of squalene from the
circulation to the atheroma may also take place (Fig.17). Most of the serum squalene was
present in LDL and HDL, in agreement with earlier studies (Miettinen 1982a, Gylling
and Miettinen 1994). Therefore, it is obvious that squalene may accumulate in the arterial
wall also because of LDL infiltration. Furthermore, lipoprotein particles were richer in
squalene in the CAD patients than in the controls, a finding which may support enhanced
squalene concentrations in atherosclerotic plaques caused by lipoprotein uptake.
   
      
               Fig.17. A proposed model of squalene origin in peripheral tissues
Serum squalene and cholesterol metabolism 
      The inverse association of the squalene-to-cholesterol ratio with serum cholesterol in
the coronary patients suggests that the higher the serum cholesterol level the lower the
squalene synthesis. This type of association was less consistent in the control women, but
was significant in those who had low squalene values. In human fibroblasts, LDL-
mediated suppression of squalene synthesis has been demonstrated (Faust et al 1979).
Serum squalene concentration most likely reflects endogenous pre-squalene cholesterol
synthesis, but its association with overall cholesterol synthesis is controversial, especially
in chronic situations (Miettinen 1970, Liu et al 1976, Miettinen 1985). In concordance
with these studies, serum squalene ratios in the present study did not reflect cholesterol
synthesis. However, in acute metabolic changes, as in diurnal variation of cholesterol
biosynthesis (Miettinen 1982a) or after LDL apheresis (Gylling et al 1998), serum
squalene ratios increase with increasing cholesterol synthesis. In humans, the active
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squalene pool that could be converted to cholesterol is very small; the active pool of
human squalene is approximately 300 mg (Liu et al 1975), and total body squalene is
estimated at 2.6 g (Liu et al 1976). Compared to other serum cholesterol precursor levels,
the squalene levels were poorly correlated with hepatic HMGCoA reductase activity and
were altered inconsistently by cholestyramine (Björkhem et al 1987) or statin treatment
(Miettinen et al 1992a). It has been shown that squalene levels were markedly higher in
the liver than in serum (Liu et al 1976, Tilvis and Miettinen 1980). Furthermore, the
squalene content of liver is poorly correlated with that of serum in hepatic-failure
patients and controls (Nikkilä et al 1992), suggesting a poor equilibration of squalene
between the hepatic and serum pool. These all partially explain the inconsistent
association between serum squalene levels and cholesterol synthesis. 
         Unlike squalene, fasting postsqualene precursors are consistently associated wit h
cholesterol synthesis (Miettinen 1969, Miettinen 1970, Miettinen 1985). Since squalene
is an early precursor of the biosynthetic chain of cholesterol it may accumulate in the
circulation due to decreased turnover to lanosterol, or due to later disturbances in the
cholesterol synthesis chain. That postsqualene precursor sterols are not evenly increased
is shown by findings that acute squalene feeding raises the serum levels of lanosterol and
other methylated precursor sterols of cholesterol, while those of demethylated ones,
occurring later in the synthesis chain, may remain unchanged (Strandberg  et al 1990).
During long-term squalene treatment only the demethylated sterols are elevated
(Miettinen and Vanhanen 1994). Low lathosterol ratios in our coronary women may
imply that their high squalene ratios are not due to a high cholesterol synthesis rate, but
reflect difficulties in further conversion of squalene to cholesterol - some being
metabolized through desmosterol, since the serum levels of squalene and desmosterol
were interrelated.
    
6.4.  Postprandial squalene and lipoprotein metabolism 
    Since the fasting serum lipids do not provide complete information on lipoproteins
during most of the day, it is relevant to evaluate the postprandial state, as well.
High fasting TGRL-apo B-48 levels in CAD women
      The synthesis and secretion of intestinally derived lipoproteins are facilitated by apo
B-48 (Glickman et al 1991, Hamilton et al 1998). The reason for high fasting TGRL-apo
B-48 in the CAD women remains unclear. During the fasting state, human intestinal
mucosa contains small amounts of apo B, and these amounts increase during fat
absorption (Glickman et al 1979). Apo B-48 is the predominent form of apo B
synthesized by the normal human intestine, and the synthesis rate of apo B-48 seems to
regulate its circulating pools (Glickman et al 1991). Following fat absorption, increased
apo B-48 levels were not related to increased apo B mRNA levels or editing (Lopez-
Miranda et al 1994). In rats, bile salt replacement and infusion of lysolecithin enhanced
apo B-48 synthesis (Davidson et al 1988), which in turn was dependent on cholesterol
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absorption (Davidson et al 1987). Thus, augmented cholesterol absorption in
hypothyroidism suppressed apo B-48 synthesis, whereas cholesterol malabsorption
induced by Surfomer administration enhanced apo B-48 synthesis. It can therefore be
assumed that apo B-48 synthesis is elevated in the CAD women due to their low biliary
cholesterol flux and reduced cholesterol absorption, as shown in Study IV. Interestingly,
fasting TGRL-apo B-48 concentration was strongly correlated with the squalene value of
the TGRL fraction in the present study, suggesting a similar intestinal origin, synthesis
rate, or both. Since expression of apo B-48 receptors was identified in macrophages and
foam cells in human atherosclerotic lesions, apo B-48-containing lipoproteins may
promote atherosclerosis directly (Brown et al 2000). 
Postprandial squalene and retinyl palmitate      
     Earlier peak times of postprandial triglycerides and apo B-48 in relation to squalene
and retinyl palmitate suggest that absorption of squalene and vitamin A was slower than
that of fat. Squalene, and to some extent retinyl esters, in contrast to triglycerides, remain
in the chylomicron and chylomicron remnants until hepatic uptake. Consequently,
lipoprotein particles of intestinal origin should become triglyceride-depleted and
squalene- and retinyl ester-enriched in the later phases of the postprandial period. In fact,
simultaneous squalene/triglyceride or retinyl palmitate/triglyceride ratios were clearly
higher in chylomicrons than in VLDL, indicating that in proportion to triglycerides, the
two markers accumulated mainly in chylomicrons throughout the postprandial period. In
VLDL, the proportional accumulation of these markers ranged from 22 to 70% of that of
chylomicrons. 
      During the fasting state, triglyceride particles of VLDL size (200-800 Å) are present
in intestinal lymph, suggesting that endogenous biliary and intestinal lipids are
transported by VLDL (Ockner et al 1969b, Jones and Ockner 1971, Tytgat et al 1971).
While their size is equal to that of hepatic VLDL, intestinal VLDL resembles
chylomicrons by containing apo B-48 (Green and Glickman 1981, Cazzolato et al 1985),
therefore, intestinal VLDL has also been regarded as small chylomicrons. A combination
of intestinal VLDL, hepatic VLDL, and chylomicron remnants constitutes the VLDL
class (<1.006 g/ml), prepared by ultracentrifugation (Fig.2). Postprandial fat transport by
intestinal lipoproteins of VLDL density is evident (Ockner et al 1969a, Tytgat et al 1971,
Karpe et al 1995, Björkegren et al 1997), as indicated also by the present data. Thus,
intestinally derived VLDL plays an important role in endogenous and exogenous fat
transport during fasting and postprandial states. The earlier peaking of squalene and
retinyl palmitate in chylomicrons than in VLDL in the control subjects, but simultaneous
peaking of chylomicrons and VLDL in the cases, suggests that chylomicron remnants
appear more rapidly from chylomicrons following lipolysis or lipoproteins of VLDL
density are directly synthezised from the intestine in the cases. 
     Although postprandial AUICs of squalene and retinyl palmitate were significantly
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correlated with each other in TGRL, as in earlier studies (Gylling and Miettinen 1994),
postprandial squalene concentration was more frequently elevated than was retinyl
palmitate in the cases and controls, probably due to efficient squalene absorption. In
contrast to the 24-h postprandial squalene concentrations in d>1.006 lipoproteins, the 24-
h retinyl palmitate levels were higher than the baseline levels; this suggests that retinyl
palmitate can be transferred from intestinally derived lipoproteins to LDL and HDL in
the later stages of the postprandial period. Furthermore, postprandial squalene peaked
almost 3 hours earlier than did retinyl palmitate in d>1.006 g/ml lipoproteins, which
contain also remnants of IDL-density. Thus, compared with vitamin A, postprandial
squalene metabolism adequately reflected postprandial lipoprotein metabolism.  
Pronounced postprandial lipoproteinemia in CAD women
     It has been demonstrated that the apo B-48 level only in postprandial IDL particles
was abnormally high  in CAD women as compared with apo B-48 in their controls with
valvular heart disease (Meyer et al 1996). The present study extends those previous
results and shows for the first time that postmenopausal women with angiographically
demonstrated CAD without HRT have enhanced postprandial levels of squalene and
apoB-48 in TGRL than have control women. The stronger postprandial rise in
intestinally derived lipoproteins may be attributed either to effective and prolonged
intestinal absorption of lipids or to their retarded clearance. Identical postprandial 4-h
curves for apo B-48 in the CAD and control groups suggest that these women’s
formation of intestinal lipoproteins was similar. The similar triglyceride response of
plasma and chylomicrons in the cases and controls after the fat meal suggests that it is
unlikely that the CAD patients had either delayed fat absorption or inefficient lipolytic
activity. In fact, lipoprotein lipase activities have been similar in women with and
without CAD (Meyer et al 1996). The higher postprandial AUICs in the case group
accounted for most for the increased areas under 4- to 24-h curves for squalene and 4- to
9-h curves for apo B-48. Furthermore, postprandial differences were more evident in the
VLDL fraction than in chylomicrons. Thus, it can be assumed that the clearance of
intestinally derived lipoproteins is diminished in CAD women, probably due to
inefficient hepatic receptor activity. 
         The magnitude of postprandial lipemia is usually associated with basal lipid and
lipoprotein levels (Nestel 1964, Patsch et al 1983, Weintraub et al 1987b). In the present
study as well, fasting serum and VLDL triglycerides and VLDL cholesterol were related
to the accumulation of postprandial lipoproteins. Serum LDL cholesterol concentration
is determined by the rate of LDL formation and catabolism. The positive association
between LDL cholesterol and postprandial TGRL particles suggests that, higher LDL
formation, lower LDL clearance, or lower cholesteryl ester transfer from LDL to TGRL,
is related to increased postprandial lipemia. Thus, baseline LDL cholesterol levels may
also predict the magnitude of postprandial lipemia in postmenopausal women. The basal
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serum squalene and apo B-48 concentrations were also associated with their postprandial
AUICs, and after being adjusted to the fasting values, the AUICs  still were significantly
higher in the cases than the controls. 
      Since influx of circulatory lipoproteins into the arterial wall is inversely related to the
size of the lipoprotein particle (Nordestgaard and Nielsen 1994), chylomicrons and large
VLDL particles (S  60-400) are unable to enter the arterial intima. These can be depositedf
in arterial tissues after conversion to remnant particles by lipoprotein lipase (Zilversmit
1979). However, a study reporting premature atherosclerosis in patients with familial
chylomicronemia due to lipoprotein lipase deficiency challenged the common view that
chylomicrons can never penetrate arterial tissues (Benlian et al 1996). In fact, direct
cholesterol transfer from chylomicrons to the arterial intima has been demonstrated
(Stender and Zilversmit 1982), and intestinally derived chylomicrons and their remnants
have been identified in the aortic intima (Mamo and Wheeler 1994, Proctor and Mam o
1998), and in atherosclerotic lesions (Gianturco and Bradley 1999) in which apo B-48
receptors have recently also been identified (Brown et al 2000). Furthermore, in men,
progression of coronary lesions is related to the postprandial plasma levels of
chylomicron remnants (Karpe et al 1994). Our results suggest that pronounced
postprandial lipoproteins play a role in the development of atherosclerosis in women, as
well. 
6.5.  Serum noncholesterol sterols and CAD
     The present study revealed for the first time the independent associations of serum
lathosterol, campesterol, and sitosterol with the presence of angiographically documented
CAD in postmenopausal women. It has been shown that low lathosterol and high plant
sterol ratios may suggest a low cholesterol synthesis rate and high cholesterol absorption
efficiency in normal subjects (Miettinen et al 1990). Thus, the independent inverse
association of lathosterol and positive associations of campesterol and sitosterol with
CAD suggest that low synthesis and high absorption of cholesterol may be related to
atherosclerosis in women independently of other lipid and nonlipid risk factors. The low
serum cholesterol precursors suggestive of low cholesterol synthesis in the CAD women
was substantiated by sterol balance data in Study IV. In contrast to serum lathosterol
concentrations, desmosterol concentrations were higher in the cases and were highly
variable because in 8 of them, mass spectrometry results indicated that desmosterol-peak
also contained 7-dehydrocholesterol, due to their similar molecular weights.
Furthermore, serum desmosterol, in contrast to lathosterol, was not associated with
cholesterol synthesis. As compared with serum desmosterol levels, the lathosterol levels
were strongly correlated with hepatic HMGCoA reductase activity (Björkhem et al
1987), suggesting that lathosterol is the better marker for cholesterol synthesis rate.
     Despite similar dietary plant sterol intake and cholesterol absorption efficiency, serum
plant sterol ratios were higher in the CAD women than in the controls, suggesting in the
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cases, either that absorption of plant sterols was increased or that biliary secretion of
plant sterols was reduced. Plant sterols would have been concentrated in the intestine due
to the reduced cholesterol pool, and thus were efficiently absorbed in the cases despite
cholesterol absorption efficiency similar to that of controls. High serum plant sterols
themselves are strongly atherogenic, especially in phytosterolemia (Glueck et al 1991,
Salen et al 1992), and plant sterols have been found in human normal arterial tissues and
atheroma (Mellies et al 1976). Furthermore, coronary patients with high baseline
cholestanol and plant sterol ratios to cholesterol appear to be clinically resistant to any
simvastatin-induced reduction in their coronary recurrence, a finding partly supported by
their further increase in plant sterol ratios during statin treatment (Miettinen et al 1998).
It remains to be shown what are the lowest plant sterol levels contributing to enhanced
CAD risk.     
6.6.  Cholesterol metabolism and CAD
    Low fecal bile acid excretion has been observed in patients with familial
hypercholesterolemia, all of whom are susceptible to development of CAD (Miettinen
and Aro 1972). Fecal bile acids and neutral steroids have tended to be low in a limited
number of CAD patients with hypercholesterolemia, but less consistently in patients with
normocholesterolemia, suggesting that impaired elimination of cholesterol is related to
CAD in the presence of hypercholesterolemia (Miettinen 1971a). A recent study
demonstrates that bile acid synthesis is lower in CAD patients than in controls, even
though only limited bile acid fractions were measured in feces (Charach et al 1998). The
present study has extended the previous results and revealed that diminished biliary
cholesterol flux into the intestine, fecal elimination of cholesterol as bile acids and
neutral steroids, and reduced cholesterol synthesis and turnover may increase the risk for
CAD in women independently of serum cholesterol levels. The perturbed cholesterol
metabolism in the CAD women may have been caused primarily by impaired hepatic
secretion of cholesterol or by low endogenous cholesterol synthesis. The latter, caused by
some unknown factors, may be responsible for low biliary cholesterol secretion. On the
other hand, lowered biliary secretion of lipids by  a “cholestasis-like” mechanism may
subsequently reduce cholesterol synthesis, a theory not substantiated by cases’ and
controls’ similar liver function tests. Lower fecal excretion of neutral steroids plus bile
acids in the cases indicates that not only the direct biliary secretion of cholesterol, but
also conversion of cholesterol to bile acids was impaired. Reduced hepatic elimination
of cholesterol overloads the hepatocytes with cholesterol, which may reduce the
expression of hepatic LDL receptors and elevate LDL or non-HDL cholesterol levels in
the circulation of the cases. However, in multivariate analysis adjusted for LDL
cholesterol levels, fecal total steroids were still associated with the risk for CAD,
suggesting that unknown mechanisms could also be involved.
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Factors influencing cholesterol metabolism
     Based on cholesterol homeostasis, cholesterol absorption, synthesis, and elimination
are interrelated. Cholesterol synthesis was inversely associated with cholesterol
absorption efficiency in the present women, in agreement with earlier findings (Miettinen
and Kesäniemi 1989). In the hepatic steady state, cholesterol synthesis and the mass of
cholesterol transported into the liver must equal the biliary secretion of lipids, and in the
whole body, cholesterol synthesis and dietary cholesterol intake must equal fecal
excretion of total steroids. Thus, cholesterol synthesis is enhanced when the fecal
excretion of steroids is high, and is suppressed when intestinal cholesterol flux to the
liver rises. Even though cholesterol absorption efficiency was similar in our cases and
controls, cholesterol mass absorption was lower in the cases due to diminished biliary
cholesterol secretion into the intestine. Here, low intestinal cholesterol flux to the liver
was, in contrast to the normal situation, unable to increase cholesterol synthesis. 
      Dietary factors modulate fecal excretion of steroids and cholesterol synthesis (Tables
1 and 2). Cholesterol feeding downregulated cholesterol synthesis and upregulated bile
acid synthesis in a long-term human study (Lin and Connor 1980), but only occasionally
in short-term studies (McNamara et al 1987, Gylling and Miettinen 1992). In contrast to
diets rich in SAFA, PUFA-rich diets increase fecal excretion of bile acids and neutral
steroids (Connor et al 1969, Nestel et al 1973, Grundy 1975). But in one study,
cholesterol synthesis was reduced by PUFA and increased by SAFA (Glatz and Katan
1993). However, the dietary recalls indicated that dietary intakes of cholesterol and fatty
acid composition were similar in the cases and controls. Furthermore, fecal plant sterols
were also similar in both groups suggesting their similar dietary plant sterol intake. 
       Hepatic secretion of cholesterol increases with age, and bile acid synthesis is
inversely correlated with age in men and women (Einarsson et al 1985). In addition,
cholesterol 7 -hydroxylation is significantly lower in elderly subjects, especially in
women, than in the middle-aged (Bertolotti et al 1993). Subjects with apo E 4 phenotypes
have higher absorption efficiency and lower synthesis of cholesterol than do those with
E 2 or E 3 phenotypes (Kesäniemi et al 1987). Cholesterol absorption efficiency is low,
whereas excretion and synthesis are high in obese subjects (Miettinen 1971b, Miettinen
1988b), and weight reduction reduces cholesterol synthesis (Leijd 1981). Cholesterol
absorption efficiency is lower in diabetic patients than in normal controls (Gylling and
Miettinen 1997). The present cases were well matched with the controls for age, BMI,
and apo E phenotypes. In addition, none of the subjects had diabetes. Accordingly, the
above confounding factors could hardly contribute to the differences in cholesterol
metabolism between the cases and controls. 
        Thyroid hormones enhance cholesterol synthesis (Abrams and Grundy 1981).
Biliary cholesterol secretion was enhanced, and the chenodeoxycholate pool was reduced
by exogenous estrogens (Everson et al 1991) and contraceptive steroids in healthy
women (Bennion et al 1976). In women with CAD, ethinyl estradiol increased
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cholesterol turnover rate (Nestel et al 1965). None of the cases and controls were on
HRT, and thyroid function was similar. Resins did not affect cholesterol absorption, but
enhanced cholesterol synthesis and fecal steroid excretion (Nazir et al 1972, Ferezou et
al 1981). Statins reduced synthesis, absorption and biliary secretion of cholesterol
(Miettinen 1991, Duane 1993, Vanhanen et al 1992, Gylling and Miettinen 1996b). In
this study, none of the participants were on hypolipidemic agents.    
Serum lipids and cholesterol metabolism
        In concordance with earlier studies (Sodhi and Kudchodkar 1973, Smith et al 1976),
cholesterol synthesis was correlated with serum triglyceride concentration. This type of
association is probably due to the correlation between cholesterol synthesis and body
weight or to enhanced secretion of newly synthezised cholesterol into the VLDL
particles. In contrast to serum triglycerides, serum cholesterol level was not associated
with cholesterol synthesis or turnover. Cholesterol turnover rates are similar in subjects
with normocholesterolemia and hypercholesterolemia (Smith et al 1976), and serum
cholesterol concentration is not directly associated with cholesterol synthesis (Nestel et
al 1969, Sodhi and Kudchodkar 1973). 
     Cholesterol metabolism and serum cholesterol levels are variably interrelated in
various clinical conditions. In obesity, activities of HMGCoA reductase, ACAT,  and
sterol 7- hydroxylase are elevated, subsequently synthesis of cholesterol and bile acids
is enhanced, but serum cholesterol level is inconsistently elevated (Miettinen 1971b,
Ståhlberg et al 1997). Acute caloric restriction has no effect on cholesterol absorption
efficiency, but reduces cholesterol synthesis and fecal bile acid excretion, as well as
plasma cholesterol level (Miettinen 1970, Kudchodkar et al 1977). Statins, which inhibit
cholesterol synthesis, also reduce biliary secretion and turnover of cholesterol (Duane
1993, Gylling and Miettinen 1992, Miettinen et al 1997) and cholesterol 7-hydroxylase
mass (Nguyen et al 1990), and markedly reduce serum cholesterol level. In the present
women, serum cholesterol concentration was correlated only with fecal bile acids.
Generally, a decreased catabolic rate of LDL caused by impaired hepatic LDL receptor
activity is directly related to hypercholesterolemia (Langer et al 1972, Brown and
Goldstein 1983, Kovanen 1987, Karjalainen et al 2000).
       
6.7.  Treatment with sitostanol ester in rapeseed oil margarine
Effects on serum lipids and cholesterol metabolism
   This study revealed that dietary sitostanol ester margarine was able to decrease LDL
cholesterol levels to <2.6 mmol/l in 32%, and to <3.4 mmol/l in 73% of the CAD
patients.Thus, one-third of the patients achieved the LDL levels recommended by of the
NCEP guidlines (Expert Panel on Detection, Evaluation, and Treatment of High Blood
Cholesterol in Adults 1993). During the home diet period, none of the cases had their
LDL levels <2.6 mmol/l and only 27% had <3.4 mmol/l of LDL cholesterol. In
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concordance with present results, a daily dosage of 3 to 3.4 g of sitostanol ester in
margarine or mayonnaise significantly reduced serum and LDL cholesterol in diabetic
and mildly hypercholesterolemic patients (Vanhanen et al 1993, Gylling and Miettinen
1996b). But, a sitostanol suspension in oil did not alter serum cholesterol level in mildly
hypercholesterolemic men on a low cholesterol diet (Denke 1995). Thus, in their ester
form, stanols reduce serum cholesterol more effectively than in the crystalline form. 
     Dietary fat and cholesterol are widely believed to affect serum cholesterol level
(Clarke et al 1997). Diets rich in cholesterol elevate serum cholesterol level, but not in all
situations (Kern 1991). The present cases had been on a low cholesterol diet, on average
247 mg/day, probably since the manifestation of their CAD. Although dietary cholesterol
amount was reduced after the margarine period, the amount of cholesterol in their diets
was not associated with the reduction in LDL cholesterol by sitostanol ester margarine.
In addition to dietary cholesterol, dietary fatty acid composition also has an impact on
blood cholesterol level. Dietary polyunsaturated fat, in contrast to saturated fat, favorably
alters serum cholesterol levels (Nestel et al 1973, Clarke et al 1997). In the present study,
replacing 21 g of dietary fat with rapeseed oil margarine increased the PUFA/SAFA ratio
in the diet and reduced serum and LDL cholesterol concentrations by 5%. The addition
of 3 g of sitostanol ester to the control margarine reduced the absorption of both dietary
and biliary cholesterol, enhanced the fecal output of neutral steroids, and further reduced
LDL cholesterol level by 15%. Furthermore, adding sitostanol ester margarine to the
diets of simvastatin-treated patients further reduced serum and LDL cholesterol by 11%
and 16%, respectively. Thus, the patients will benefit by using sitostanol ester margarine
to lower their blood cholesterol levels.    
      The mechanisms by which plant sterols and stanols reduce serum cholesterol levels
have been suggested. It has been demonstrated since the 1950s that the mass and
percentage of cholesterol absorption are reduced after addition of plant sterols or plant
stanols (Hernandez et al 1953, Grundy et al 1969, Heinemann et al 1991, Vanhanen et al
1994, Gylling and Miettinen 1996b). Sitosterol in high concentration restricts micellar
incorporation of cholesterol (Ikeda and Sugano 1983). In fact, sitosterol has greater
miceller solubilities than has cholesterol (Armstrong and Carey 1987). Sitosterol
hindered (Hernandez et al 1953) or failed to hinder (Ikeda et al 1988) esterification of
cholesterol in the intestinal mucosal cell . However, the overall result is a reduction in
cholesterol absorption, which could lead to cholesterol lowering,  suggested by the
association between the changes in cholesterol absorption efficiency and those in LDL
levels found in the present study. Reduction in cholesterol absorption resulted in
increased fecal output of neutral steroids and in synthesis and turnover of cholesterol.
The inverse association between cholesterol synthesis and cholesterol absorption
efficiency during both the home diet and the margarine period in our patients indicate s
that low cholesterol absorption may be compensated for high cholesterol synthesis,
despite  the subjects’ normal or altered cholesterol absorption efficiency values. An
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increase in cholesterol synthesis by plant stanol esters may enhance biliary cholesterol
secretion. This remains to be elucidated.
Hyper-responders to sitostanol esters
      There was a variation in response to sitostanol ester margarine in the study
population. Who, then, responded efficiently to the treatment? High serum ratios of
cholestanol to cholesterol and low respective values for precursor sterols predicted those
patients most responsive to sitostanol-induced cholesterol malabsorption. The higher the
baseline cholesterol absorption efficiency, the higher was its absolute reduction by
sitostanol ester. The highest reduction in serum and LDL cholesterol level was shown by
the patients with the highest respective baseline values. Furthermore, those with high
serum plant sterol and cholestanol ratios and with low precursor sterol ratios had a
marked reduction in serum cholesterol level. This suggests that sitostanol ester margarine
is most effective in patients in whom cholesterol absorption is high and cholesterol
synthesis is low. A recent study has suggested that coronary patients with high synthesis
and low absorption of cholesterol, but not those with low synthesis and high absorption
responded to a simvastatin-induced reduction in major coronary events (Miettinen et al
1998). Thus, the patients with high synthesis, nonresponders to sitostanol, should
beneficially respond to statins. A synergistric effect of statins and sitostanol esters has
been reported earlier in hypercholesterolemic non-insulin-dependent diabetic men
(Gylling and Miettinen 1996b) and in familial hypercholesterolemic patients (Vuorio et
al 2000). Accordingly, a combination of cholesterol synthesis inhibition by statins with
malabsorption by sitostanol esters is beneficial in a wide range population, reduces the
needed statin dose and may improve the response to secondary prevention. A recent
animal experimental study revealed that reducing cholesterol level by sitostanol delayed
plaque formation in coronary arteries (Ntanios et al 1998).        
6.8.  The effects of sitostanol ester margarine and of simvastatin on squalene
     Control rapeseed oil margarine reduced serum squalene levels and ratios to
cholesterol and raised fecal squalene output, without any increase in serum cholesterol
precursors or in cholesterol synthesis. In normal subjects, dietary intake of rapeseed oil
(double of the present dose) increased serum cholestenol and lathosterol ratios, but serum
squalene was not altered (Miettinen and Vanhanen 1994). Thus, rapeseed oil margarine
can significantly affect squalene metabolism without affecting cholesterol metabolism
only in CAD women. Rapeseed oil is rich in mono- and polyunsaturated fats, but it
contains only little squalene (2.4 mg/100 g rapeseed oil). A high dietary intake of PUFA
has been able to reduce cholesterol absorption and increase fecal steroid output (Conner
et al 1969, Nestel et al 1973, Grundy 1975), but in the CAD women, a mean intake of 11
g/day had no effect on cholesterol metabolism. 
     In addition to cholesterol lowering, sitostanol ester margarine reduced serum squalene
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levels by about 15% and also reduced significantly LDL and HDL triglycerides from
their home diet values. These reductions are in concordance with the finding in Study I
that high serum squalene concentration was associated with high serum triglyceride
concentration. However, the reduction in VLDL triglycerides and in ratios of squalene
to cholesterol was not significant. The latter was probably due to more efficient reduction
of cholesterol than of squalene levels by sitostanol ester. In diabetic (Gylling and
Miettinen 1996b) or modestly hypercholesterolemic patients (Vanhanen et al 1994),
sitostanol ester failed to alter serum squalene levels. In our patients, fecal squalene output
only tended to rise, even though other precursor sterols were significantly elevated by
sitostanol ester. Thus, increasing cholesterol synthesis by sitostanol ester has less effect
on serum squalene than on precursor sterol concentrations. Statin reduced cholesterol
synthesis as suggested by the reduction in serum cholesterol precursors. But serum
squalene values were virtually unaltered. Earlier studies also demonstrated that statin
treatment did not alter serum squalene ratios (Miettinen et al 1992a, Uusitupa et al 1992,
Vanhanen et al 1992), although lovastatin treatment reduced the squalene ratios in
patients with type III hyperlipoproteinemia (Gylling et al 1995a). Fibrates, which are
usually used to reduce serum triglyceride levels, also reduced squalene values (Nestel
and Kudchodkar 1975, Miettinen et al 1992a). Either our combination of statin and
sitostanol ester induced reductions in cholesterol absorption, or cholesterol synthesis had
an effect on serum squalene levels. In pravastatin-treated hypercholesterolemic patients,
sitostanol ester (1.5 g/day) did not alter serum squalene or other cholesterol precursors
(Vanhanen 1994). Thus, reduction of serum squalene needs further exploration.     
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7.  SUMMARY AND CONCLUSIONS
      Squalene is a nonsterol precursor of cholesterol, but its serum level is inconsistently
associated with total body cholesterol metabolism. Therefore, in addition to the
conventional CAD risk factors, baseline squalene levels in serum and lipoproteins and
postprandial squalene and cholesterol absorption, synthesis and elimination were
investigated in 50- to 55-year-old postmenopausal women with and without CAD.
Furthermore, the effects of inhibiting cholesterol absorption by sitostanol ester alone and
combined with cholesterol synthesis inhibition by statin on serum squalene level were
studied in CAD patients.     
    The CAD patients (n=48) were recruited from University Central Hospital of Helsinki
and the controls (n=61) from the population registry of Helsinki. Serum squalene and
sterols were measured by gas-liquid chromatography. Cholesterol metabolism was
assessed by measuring cholesterol absorption and sterol balance, and postprandial
squalene and lipoprotein metabolism was determined after administration of a fat meal
containing squalene and vitamin A. Correspondingly, postprandial levels of squalene,
cholesterol, triglycerides, retinyl palmitate, and apolipoprotein  B-48 were measured in
chylomicrons, VLDL, and d>1.006 lipoproteins.
    The CAD women had comparable serum total cholesterol levels, but higher LDL
cholesterol and lower HDL cholesterol level than did healthy controls. Although the
frequency of  smokers, hypertension, and family history of CAD and serum levels of
hemoglobin and glycosylated hemoglobin A1c were higher in the cases than in controls,
only the high A1c and family history of CAD were associated with CAD in multivariate
analysis.
       Serum squalene level and ratio to cholesterol were higher in the cases than in the
controls throughout the quartiles of serum cholesterol level. In multivariate analysis, after
adjustment for body mass index, family history of CAD, smoking, hypertension, LDL
and HDL cholesterol, and glycosylated hemoglobin A1c, the presence of CAD was
independently associated with serum squalene ratio. Dietary squalene intake was
minimal in our subjects, but compared with controls, the cases had lower fecal squalene
excretion. The latter was positively related to cholesterol synthesis and biliary secretion
of cholesterol, suggesting that biliary squalene secretion was low in CAD women. Serum
squalene ratios did not vary with respect to cholesterol synthesis but were inversely
related to biliary lipid secretion. Fasting serum squalene was mainly carried by d>1.006
lipoproteins, and it was significantly elevated in chylomicrons, VLDL, and d>1.006
lipoproteins of the CAD versus control women. This phenomenon may be related to the
earlier findings for squalene in human atheromatous plaques. The squalene content of
lipoproteins was correlated with cholesterol and triglycerides, especially in VLDL. The
cases also had higher postprandial squalene levels in chylomicrons and VLDL. The
postprandial squalene levels were associated with those of the baseline serum level such
that the postprandial squalene responses in these lipoproteins could be predicted by
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measurement of baseline serum squalene. In addition, postprandial apolipoprotein B-48
level in triglyceride-rich lipoproteins and retinyl palmitate in VLDL were higher in the
cases, suggesting that clearance of postprandial lipoproteins in general was retarded.
VLDL peaked simultaneously with chylomicrons and rapidly appeared in the circulation
of CAD women. This observation may be of clinical relevance, since VLDL-sized
particles can penetrate arterial intima and thus be atherogenic.
      After adjustment for other conventional risk factors, the presence of CAD was
independently and inversely associated with reduced synthesis, turnover, biliary
secretion, intestinal pool, absorption, and fecal elimination of cholesterol. Compared with
the controls, the CAD women had lower serum lathosterol, but had higher serum
desmosterol. Since cholesterol synthesis was lower in the cases than in controls, this high
serum desmosterol was  probably due to enhanced squalene cyclization via the
unsaturated side-chain pathway, or due to disturbances in desmosterol metabolism to
cholesterol. Serum plant sterol levels were higher in the cases than in controls, despite
their similar dietary plant sterol intake and cholesterol absorption efficiency. Thus, the
high serum levels of plant sterols in the cases probably resulted from efficient absorption
of plant sterols from their reduced intestinal cholesterol pools. LDL and HDL cholesterol
levels were related to bile acid synthesis, which tended to be lower in the CAD women.
        Sitostanol ester in rapeseed oil margarine reduced cholesterol absorption efficiency
and reduced total absorbed mass of cholesterol and enhanced fecal neutral steroid
excretion. The serum concentrations of squalene, cholesterol, and plant sterols were
reduced, but the ratio of squalene to cholesterol remained unchanged. Neither cholesterol
synthesis inhibition by statin nor the combined effect of statin and sitostanol altered
serum squalene ratios. Thus, altering cholesterol metabolism had only minor effects on
squalene metabolism. 
       In conclusion, altered squalene metabolism reflected by high fasting serum and
postprandial lipoprotein squalene levels and low fecal and biliary squalene outputs can
predispose postmenopausal women to atherosclerosis. Furthermore, the presence of CAD
is associated with low synthesis and elimination of cholesterol and retarded clearance of
postprandial lipoproteins. Cholesterol malabsorption induced by sitostanol ester
margarine and inhibition of cholesterol synthesis by statin can both beneficially alter
abnormal cholesterol metabolism and lower serum cholesterol, but not squalene level.
Quantification of basal serum squalene and noncholesterol sterols reflects postprandial
lipoprotein clearance and cholesterol metabolism that cannot be predicted from serum
and lipoprotein lipid measurements alone, and so provides additional information on the
risk for CAD in postmenopausal women.  
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